10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-21-163695.txt : 20210517 0001193125-21-163695.hdr.sgml : 20210517 20210517161454 ACCESSION NUMBER: 0001193125-21-163695 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NexImmune, Inc. CENTRAL INDEX KEY: 0001538210 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40045 FILM NUMBER: 21930770 BUSINESS ADDRESS: STREET 1: 9119 GAITHER ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-825-9810 MAIL ADDRESS: STREET 1: 9119 GAITHER ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 10-Q 1 d277349d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-

NEXIMMUNE, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware		45-2518457
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

9119 Gaither Road Gaithersburg, MD		20877
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (301) 825-9810

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

NEXI

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 31, 2021, the registrant had 22,579,219 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents


		Page
	Special Note Regarding Forward-Looking Statements		1
PART I.	FINANCIAL INFORMATION		3
Item 1.	Financial Statements (Unaudited)		3
	Balance Sheets		3
	Statements of Operations and Comprehensive Loss		4
	Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Deficit		5
	Statements of Cash Flows		6
	Notes to Unaudited Financial Statements		7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		25
Item 4.	Controls and Procedures		25

PART II.	OTHER INFORMATION		26
Item 1.	Legal Proceedings		26
Item 1A.	Risk Factors		26
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		26
Item 3.	Defaults Upon Senior Securities		27
Item 4.	Mine Safety Disclosures		27
Item 5.	Other Information		27
Item 6.	Exhibits		27

Signatures			29

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

•

our ability to obtain and maintain regulatory approval of NEXI-001 and NEXI-002 and/or our other product candidates;

•

our ability to successfully commercialize and market NEXI-001 and NEXI-002 and/or our other product candidates, if approved;

•

our ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;

•

the potential market size, opportunity and growth potential for NEXI-001 and NEXI-002 and/or our other product candidates, if approved;

•

our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize NEXI-001 and NEXI-002 and/or our other product candidates, if approved;

•

our ability to obtain funding for our operations;

•

the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;

•

the timing of anticipated regulatory filings;

•

the timing of availability of data from our clinical trials;

•

the impact of the ongoing COVID-19 pandemic and our response to it;

•

the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;

•

our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

•

our ability to advance product candidates into, and successfully complete, clinical trials;

•

our ability to recruit and enroll suitable patients in our clinical trials;

•

the timing or likelihood of the accomplishment of various scientific, clinical, regulatory and other product development objectives;

•

the pricing and reimbursement of our product candidates, if approved;

•

the rate and degree of market acceptance of our product candidates, if approved;

•

the implementation of our business model and strategic plans for our business, product candidates and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

•

developments relating to our competitors and our industry;

•

the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;

•

the development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the future impact of it and COVID-19 on our clinical trials, business operations and funding requirements; and

•

our financial performance.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section and elsewhere in this Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable as of the date of this Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Form 10-Q to conform these statements to new information, actual results or to changes in our expectations, except as required by law.

You should read this Form 10-Q and the documents that we reference in this Form 10-Q and have filed with the Securities and Exchange Commission, or SEC, as exhibits to this Form 10-Q with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

NEXIMMUNE, INC.

BALANCE SHEETS


	March 31, 2021			December 31, 2020
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	118,102,945		$	5,031,079
Restricted cash		67,500			67,500
Prepaid expenses and other current assets		4,788,019			3,293,858

Total current assets		122,958,464			8,392,437
Property and equipment, net		3,584,412			2,885,260
Other non-current assets		23,373			23,373

Total assets	$	126,566,249		$	11,301,070

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	2,406,537		$	2,760,129
Accrued expenses		2,842,998			2,603,027
Derivative liability		—			1,702,359
Other current liabilities		843,619			843,619
Convertible notes issued to related parties		—			7,324,267
Convertible notes		—			11,793,397

Total current liabilities		6,093,154			27,026,798

Deferred rent, net of current portion		11,764			23,529
Other non-current liabilities		—			4,935

Total liabilities		6,104,918			27,055,262

Commitments and contingencies
Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of March 31, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of $42,314,789 as of December 31, 2020.		—			35,047,435
Series A-2 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of March 31, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of $8,683,746 as of December 31, 2020.		—			7,685,865
Series A-3 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of March 31, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of $11,699,176 as of December 31, 2020.		—			10,887,449

Total redeemable convertible preferred stock		—			53,620,749
Stockholders’ deficit
Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,579,219 issued and outstanding as of March 31, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020.		2,258			126
Additional paid-in-capital		205,847,571			8,206,938

Accumulated deficit		(85,388,498	)		(77,582,005	)

Total stockholders’ deficit		120,461,331			(69,374,941	)

Total liabilities, redeemable convertible preferred stock and stockholders’ deficit	$	126,566,249		$	11,301,070

The accompanying notes are an integral part of these unaudited financial statements.

NEXIMMUNE, INC.

STATEMENTS OF OPERATIONS

(unaudited)


	Three Months Ended March 31,
	2021			2020
Revenue	$	—		$	—
Operating expenses:
Research and development		6,012,608			4,272,167
General and administrative		4,057,592			2,088,401

Total operating expenses		10,070,200			6,360,568
Loss from operations		(10,070,200	)		(6,360,568	)
Other (expense) income:
Interest income		3,613			18,684
Interest expense		(904,119	)		(989	)
Change in fair value of derivative liability		2,424,877			—
Other income (expense)		(722	)		27,365

Other income (expense)		1,523,649			45,060

Net loss	$	(8,546,551	)	$	(6,315,508	)
Accumulated dividends on Redeemable Convertible Preferred Stock		(377,562	)		(815,516	)

Net loss available to common stockholders’	$	(8,924,113)		$	(7,131,024	)

Basic and diluted net loss available to common stockholders per common share	$	(0.71)		$	(5.68	)

Basic and diluted weighted-average number of common shares outstanding		12,633,123			1,254,681

STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)


	For the Three Months Ended March 31,
	2021			2020
Net loss	$	(8,546,551	)	$	(6,315,508	)

Other comprehensive loss:
Unrealized (loss) gain on available-for-sale marketable securities, net of tax		—			(506)

Comprehensive loss	$	(8,546,551	)	$	(6,316,014	)

The accompanying notes are an integral part of these unaudited financial statements.

STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

Three Months Ended March 31, 2021 and 2020


	Redeemable Convertible Preferred Stock																		Stockholders’ Deficit
	Series A						Series A-2						Series A-3						Common Stock				Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income/ (Loss)			Total Stockholders Deficit
	Shares			Amount			Shares			Amount			Shares			Amount			Shares		Amount		Additional Paid-In Capital			Accumulated Deficit			Accumulated Other Comprehensive Income/ (Loss)			Total Stockholders Deficit
Balance at January 1, 2021		121,735,303		$	35,047,435			22,047,361		$	7,685,865			31,209,734		$	10,887,449			1,256,609	$	126	$	8,206,938		$	(77,582,005	)	$	—		$	(69,374,941	)
Cumulative effect of adoption of accounting standard		—			—			—			—			—			—			—		—		(2,277,332	)		740,058			—			(1,537,274	)
Issuance of Series A redeemable preferred stock upon exercise of warrants		145,000			1,450			—			—			—			—			—		—		—			—			—			—
Conversion of preferred stock into common stock		(121,880,303	)		(35,048,885	)		(22,047,361	)		(7,685,865	)		(31,209,734	)		(10,887,449	)		10,144,052		1,014		53,621,185			—			—			53,622,199
Conversion of convertible debt into common stock		—			—			—			—			—			—			3,669,010		367		30,251,689			—			—			30,252,056
Issuance of common stock in connection with the initial public offering. net of transaction costs		—			—			—			—			—			—			7,441,650		744		114,550,571			—			—			114,551,315
Exercise of stock options		—			—			—			—			—			—			65,013		7		297,076			—			—			297,083
Exercise of warrants		—			—			—			—			—			—			2,896		—		—			—			—			—
Stock-based compensation		—			—			—			—			—			—			—		—		1,197,444			—			—			1,197,444
Net loss		—			—			—			—			—			—			—		—		—			(8,546,551	)		—			(8,546,551	)

Balance at March 31, 2021		—		$	—			—		$	—			—		$	—			22,579,219	$	2,258	$	205,847,571		$	(85,388,498	)	$	—		$	120,461,331


Balance at January 1, 2020		121,735,303		$	35,047,435			22,047,361		$	7,685,865			31,209,734		$	10,887,449			1,254,681	$	126	$	4,705,808		$	(47,716,008	)	$	506		$	(43,009,568	)
Stock-based compensation		—			—			—			—			—			—			—		—		318,962			—			—			318,962
Change in unrealized gains on marketable available-for-sale securities		—			—			—			—			—			—			—		—		—			—			(506	)		(506	)
Net loss		—			—			—			—			—			—			—		—		—			(6,315,508	)		—			(6,315,508	)

Balance at March 31, 2020		121,735,303		$	35,047,435			22,047,361		$	7,685,865			31,209,734		$	10,887,449			1,254,681	$	126	$	5,024,770		$	(54,031,516	)		—		$	(49,006,620	)

NEXIMMUNE, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended March 31,
	2021			2020
Cash flows from operating activities
Net loss	$	(8,546,551	)	$	(6,315,508	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		174,331			143,518
Gain (loss) on asset disposal		(464	)		398
Stock-based compensation		1,197,444			318,962
Non-cash interest expense		903,919			—
Change in fair value of derivative liability		(2,424,877	)		—
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(2,446,793	)		(929,007	)
Accounts payable		(645,847	)		(191,877	)
Accrued expenses, deferred rent and other		633,307			463,090

Net cash used in operating activities		(11,155,532	)		(6,510,424	)
Cash flows from investing activities
Purchase of property and equipment		(581,228	)		(241,519	)
Proceeds from disposal of equipment		464			550
Employee advances		—			(494	)
Proceeds from maturities and sales of available-for-sale marketable securities		—			999,780

Net cash provided by (used in) investing activities		(580,764	)		758,317
Cash flows from financing activities
Proceeds from initial public offering, net of transaction costs		115,503,948			—
Proceeds from the exercise of stock options		297,083			—
Proceeds from the exercise of warrants		1,450			—
Principal payments on capital leases		(5,212	)		(4,832	)
Proceeds from the issuance of convertible notes from related parties		56,500			—
Proceeds from the issuance of convertible notes		8,974,980			—
Issuance costs associated with convertible notes		(20,587	)		—

Net cash provided by (used in) financing activities		124,808,162			(4,832	)
Net increase (decrease) in cash, cash equivalents and restricted cash		113,071,866			(4,097,908	)
Net cash, cash equivalents and restricted cash at beginning of period		5,098,579			9,196,487

Net cash, cash equivalents and restricted cash at end of period	$	118,170,445		$	5,098,579

Supplemental disclosure of cash flow information:
Cash paid during the year for interest	$	200		$	1,999

Supplemental disclosure of noncash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$	292,255		$	7,887

The accompanying notes are an integral part of these unaudited financial statements.

NEXIMMUNE, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

1. Nature of the business and basis of presentation

NexImmune, Inc. (the “Company” or “NexImmune”), a Delaware corporation headquartered in Gaithersburg, Maryland, was incorporated on June 7, 2011. The Company is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are AIM nanoparticles, which act as synthetic dendritic cells. These AIM nanoparticles can be programmed to present specific antigens and co-stimulatory signals to specific T cells, generating an immune response that can be directed toward any foreign substance or cell type in a patient’s body. The Company’s first two products, both for the treatment of different types of cancer, entered clinical trials in 2020.

2. Basis of Presentation

Basis of Presentation

The accompanying unaudited financial statements were prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). These financial statements should be read in conjunction with our audited financial statements and the accompanying notes to our financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 31, 2021.

In our management’s opinion, the accompanying financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of March 31, 2021 and December 31, 2020, and our statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders’ deficit, and cash flows for the three month periods ended March 31, 2021 and 2020. Interim results are not necessarily indicative of results for an entire year.

Recent accounting standards and pronouncements

Recently Adopted

In August 2020, the FASB issued ASU 2020-06, an update to ASC Topic 470, Subtopic - 20, Debt - Debt with Conversion and Other Options, and ASC Topic 815, Subtopic – 4, Derivatives and Hedging - Contracts in Entity’s Own Equity. ASU 2020-06 simplifies the guidance for certain financial instruments with characteristics of liability and equity, including convertible instruments and contracts on an entity’s own equity by reducing the number of accounting models for convertible instruments and amends guidance in ASC Topic 260, Earnings Per Share, relating to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. ASU 2020-06 is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2021, with early adoption permitted for fiscal years that begin after December 15, 2020. The Company early adopted this standard effective January 1, 2021 using the modified retrospective method. Under this standard, only conversion features embedded in the debt instrument that are accounted for as derivatives in accordance with ASC 815 or under the substantial premium model in ASC 470, require separate accounting. Prior to the adoption of this standard, the Company had recorded a beneficial conversion feature as a discount to convertible notes issued. Upon adoption of this standard, the beneficial conversion feature is no longer separately bifurcated. As a result of applying the modified retrospective method, the Company recognized a transition adjustment of $0.7 million recorded in accumulated deficit, a reduction of additional paid-in capital of $2.2 million and an increase to the carrying value of the convertible notes of $1.5 million on January 1, 2021.

Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The guidance requires lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption. Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements. In November 2019, the FASB issued ASU 2019-10 deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU 2020-05 which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The Company is currently reviewing its leases and other contracts to determine the impact the adoption of this guidance will have on the financial statements. The Company currently expects that the adoption of this guidance will change the way it accounts for its operating leases, and will result in recording right-of-use assets and lease liabilities in the balance sheets, and result in additional lease-related disclosures in the footnotes to the financial statements. The Company expects that it will adopt this guidance utilizing the modified retrospective approach and elect the package of practical expedients.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326), which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December 15, 2022, and interim periods beginning after December 15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company’s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU 2016-13 is not expected to have a material impact on its financial position, results of operations or the related disclosures.

3. Cash and Cash Equivalents and Restricted cash

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows.


	March 31, 2021		December 31, 2020
Cash and cash equivalents	$	118,102,945	$	5,031,079
Restricted cash		67,500		67,500

Total	$	118,170,445	$	5,098,579

Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.

Amounts included in restricted cash represent those required as collateral on corporate credit cards.

4. Fair Value Measurements

The Company’s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of March 31, 2021 and December 31, 2020 due to their short-term maturities. The Convertible Notes as discussed in Note 10 contain embedded derivative features that are required to be bifurcated and remeasured to fair value at each reporting period.

The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (“ASC 820”). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 -

Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2 -

Fair value is determined by using inputs, other than Level 1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.

Level 3 -

Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.

In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.

The Company’s derivative liability related to certain features embedded within the Company’s Convertible Notes as discussed in Note 10. The derivative is accounted for as a liability and remeasured to fair value as of each balance sheet date until the Convertible Note is settled or cancelled. The Convertible Notes were converted into shares of common stock upon the Company’s completion of the Initial Public Offering (“IPO”) on February 11, 2021. The related remeasurement adjustments are recognized in the accompanying statements of operations.

During the period ended March 31, 2021 and December 31, 2020 the Company did not have any transfers between levels. There were no Level 3 recurring fair value measurements as of March 31, 2021. The following table presents activity related to the Company’s fair value measurements categorized as Level 3 of the valuation hierarchy, valued on a recurring basis:


Balance as of December 31, 2020	$	1,702,359
Fair value of derivative liabilities issued		722,518
Reduction in expense related to fair value changes in derivative liabilities		(2,424,877	)

Balance as of March 31, 2021	$	—

The fair value of the derivative liability was determined using a binomial lattice model by calculating and comparing the fair value of the Convertible Notes with and without the embedded features.

Key inputs into this valuation model are ( l) the probability of various events which result in conversion prior to the maturity of the Convertible Notes; (2) the estimated timing of conversion; (3) time period to maturity; (4) the fair value of the Company’s stock underlying the Convertible Notes within each scenario; (5) the expected volatility of the Company’s stock through the various events resulting in conversion; (6) the risk-adjusted discount rate; and (7) the Company’s stock dividend yield.

The recurring Level 3 fair value measurements of the embedded features of the Convertible Notes issued in January 2021 include the following significant unobservable inputs:


Unobservable Input		Assumptions
Probabilities of conversion provisions		5%-50%
Estimated timing of conversion (years)		0.13-0.31
Time period to maturity (years)		0.31
Fair value of the Company’s stock		$0.45-$0.56
Stock price volatility		76-90%
Risk-adjusted discount rate		25.56%
Dividend yield		0%

Significant changes to these assumptions would result in increases or decreases to the fair value of the derivative liability. There were no Convertible Notes issued after January 2021. Immediately before the conversion of the Convertible Notes on February 11, 2021, the derivative liability was remeasured to fair value which the Company concluded was immaterial. The derivative liability was remeasured to zero. All derivative instruments were eliminated following the conversion of the Convertible Notes on February 11, 2021.

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following at March 31, 2021 and December 31, 2020:


	March 31, 2021		December 31, 2020
Prepaid research and development expenses	$	1,922,643	$	1,894,785
Prepaid maintenance agreements		113,059		144,575
Prepaid insurance		2,608,493		98,421
Prepaid other		143,824		124,929
Deferred financing costs		—		952,633
Other current assets		—		78,515

	$ 4,788,019		$ 3,293,858

6. Property and Equipment

Property and equipment consist of the following at March 31, 2021 and December 31, 2020:


	March 31, 2021			December 31, 2020
Laboratory equipment	$	4,631,962		$	3,801,545
Computer equipment and software		336,524			305,214
Furniture and fixtures		47,877			47,877
Leasehold improvements		167,972			153,965

		5,184,335			4,308,601
Less accumulated depreciation and amortization		(1,599,923	)		(1,423,341	)

Property and equipment, net	$	3,584,412		$	2,885,260

Depreciation and amortization expense was $174,331 and $141,178 for the three months ended March 31, 2021 and 2020, respectively.

7. Accrued Expenses

A summary of the components of accrued expenses is as follows as of March 31, 2021 and December 31, 2020:


	March 31, 2021		December 31, 2020
Accrued professional fees	$	135,033	$	135,033
Accrued salaries, benefits and related expenses		2,567,071		1,924,405
Accrued severance		—		26,724
Accrued interest		3,491		408,315
Other accrued expenses		137,403		108,550

	$ 2,842,998		$ 2,603,027

8. Commitments and Contingencies

Maryland Biotechnology Center Grant

The Company entered into a Translational Research Award Agreement effective May 23, 2012 with the Department of Business & Economic Development with the State of Maryland, Maryland Biotechnology Center (“MBC”). The mission of MBC is to integrate entrepreneurial strategies to stimulate the transformation of scientific discovery and intellectual assets into capital formation and business development. Under the agreement, MBC provided $200,000 to NexImmune for research on its artificial aAPC for cancer immunotherapy. In 2013, an amendment increased the amount by $125,000 for a total grant of $325,000. This grant was recorded as income in 2012 and 2013, as the Company incurred the expenses which qualified it for the grant.

The Company must repay the funds through annual payments calculated at 3% of annual revenues for the preceding year. Payments shall continue for 10 years after the first payment date and may total up to 200% of the total grant amount. The end date of the agreement is defined as January 31, 2024, or when any and all repayments due to MBC have been made. If the Company does not earn any revenue, the grant does not need to be repaid. Through March 31, 2021, no revenue has been recorded, therefore, no payments to MBC are due.

Johns Hopkins University Exclusive License Agreement

The Company entered into an Exclusive License Agreement with Johns Hopkins University (“JHU”) effective June 2011, which was amended and restated in January 2017, under which there are license fees, royalties, and milestone payments. As part of the agreement, the Company acquired a perpetual, exclusive license from JHU covering its invention related to Antigen Specific T cells. In consideration for the Exclusive License Agreement, the Company made an upfront payment of $155,000 and issued 26,918 shares of Common Stock.

JHU was also entitled to milestone fees of $75,000 in connection with clinical trial milestones. For the first licensed product or licensed service in the therapeutic field, the Company may be required to pay JHU additional aggregate milestone fees of $1.6 million for clinical and regulatory milestone fees. The Company may be required to pay JHU reduced milestone fees for the second and third licensed products or licensed services in the therapeutic field in connection with clinical and regulatory milestones. In the diagnostic field, the Company may be required to pay JHU aggregate milestone fees of $400,000 for the first licensed product or licensed service and reduced milestone fees for the second and third licensed products or licensed services in connection with regulatory and commercial milestones. The Company may be required to pay JHU aggregate milestone fees of $100,000 for commercial milestones for the first licensed product or licensed service in the non-clinical field. In the aggregate, the Company may be required to pay JHU additional milestone fees of up to $4.2 million for all clinical, regulatory and commercial milestones for all licensed products or licensed services in the therapeutic field, the diagnostic field and the non-clinical field. The Company may also be required to pay royalties in the low to upper mid-single digits on net sales of therapeutic products, diagnostic products and non-clinical products. The Company is required to make minimum annual royalty payments of $100,000 to JHU under the A&R JHU License Agreement through the term of the agreement. The Company may also be required to pay JHU a low double digit percentage of any non-royalty sublicense consideration we receive.

The Company will record a liability when such events become probable. The Company has not reached any of the milestones or transacted its first commercial sale as of March 31, 2021.

The Company must make minimum royalty payments, which began upon the 4th anniversary of the agreement and upon every anniversary thereafter during the term of the agreement, which offset future royalties per above owed to JHU. The Company has incurred $350,000 in cumulative minimum royalties from inception. Future annual minimum royalties consist of $100,000 due each year during the remaining term of the agreement. The Company records milestones, royalties and minimum royalties at the time when payments become probable. During the three months ended March 31, 2021 and 2020, the Company incurred $25,000 each quarter, related to minimum royalties owed, included in research and development expenses on the accompanying statement of operations. The Company has accrued royalties of $75,000 as of March 31, 2021 and 2020.

Paycheck Protection Program Loan

On April 23, 2020, the Company applied for an unsecured $843,619 loan under the Paycheck Protection Program (the “PPP Loan”). The Paycheck Protection Program (or “PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On May 1, 2020, the PPP loan was approved and funded. The Company entered into a promissory note of $843,619, which is recorded within other current liabilities in the accompanying balance sheet. The Company treats the PPP loan as debt under ASC 470. The use of loan proceeds must be for payroll costs, payment of interest on covered mortgage obligations, rent and utility costs over either an eight-week or 24-week period, at the Company’s option.

The PPP Loan has a maturity date of April 23, 2022 and accrues interest at an annual rate of 0.98%. Interest and principal payments are deferred for the first six months of the loan. Thereafter, monthly interest and principal payments are due until the loan is fully satisfied. The promissory note evidencing the PPP Loan contains customary events of default resulting from, among other things, default in the payments.

The PPP Loan indebtedness may be forgiven in whole or in part upon request and the Company must provide documentation in accordance with the SBA requirements and the Company must certify that the amounts requested to be forgiven qualify under those requirements. The SBA may approve or deny the Company’s loan forgiveness application, in whole or part. The amount of potential loan forgiveness may be reduced if NexImmune fails to maintain employee and salary levels during the applicable eight-week or 24-week period following receipt of the loan proceeds. The Company submitted the PPP Loan forgiveness application in March 2021. The Company cannot provide any objective assurance that it will obtain forgiveness in whole or in part.

Contingencies

From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of March 31, 2021 and December 31, 2020, the Company was not involved in any material legal proceedings.

9. Convertible Notes

During April 2020, the Company authorized the sale of up to $15,000,000 6% Convertible Notes (“Agreement”). The Agreement specified an initial closing date of April 23, 2020 and allowed additional closings within 90 days of the initial closing. The Convertible Notes had a scheduled maturity date of April 23, 2021.

The terms of the Convertible Notes required a mandatory conversion upon certain qualified financing events (“Mandatory Conversion”) and allowed for conversion at the option of the holder upon certain non-qualified financing events (“Optional Conversion 1”). Upon Mandatory Conversion and Optional Conversion 1, the outstanding principal amount and all accrued and unpaid interest would automatically convert into the Company’s preferred stock of the same series issued in such equity financing and would be equal to the number of preferred stock obtained by dividing (a) all principal and accrued but unpaid interest under such Convertible Note by (b) the price per share paid by the other purchasers of the preferred stock sold in such equity financing multiplied by 80%.

If the Mandatory Conversion and Optional Conversion 1 did not occur by the maturity date, the outstanding principal amount plus all accrued and unpaid interest would be converted at the option of the holder into Company’s common stock at the price per share obtained by dividing $85 million by the Company’s fully-diluted capitalization (“Optional Conversion 2”).

If the Company (i) consummates a change in control or (ii) the Company’s common stock becomes publicly listed on a stock exchange, the outstanding principal amount plus all accrued and unpaid interest would automatically convert into shares of the Company’s most senior series of capital stock outstanding at the time of such change in control or public listing, at a price equal to the lower of (a) 90% of the price per share paid by the purchasers of such stock in such a transaction and (b) the price per share obtained by dividing $125 million by the Company’s fully-diluted capitalization (“Change in Control”).

The Agreement was amended in July 2020 to allow the sale of up to $50,000,000 convertible notes and to allow for additional closings within 150 days of the initial closing date. The Agreement was amended in September 2020 to allow for additional closings within 190 days of the initial closing date. In addition, the provisions of Mandatory Conversion and Optional Conversion 1 were amended to allow for conversion upon an equity financing at a price equal to the lower of (a) 80% of the price per share paid by the purchasers of such stock in such a transaction and (b) the price per share obtained by dividing $125,000,000 by the Company’s fully-diluted capitalization. The Company evaluated the amendments and concluded that the amendments represented a debt modification.

In October 2020, the Agreement was further amended to allow additional closings through December 31, 2020, and in January 2021 it was amended again to allow closings through January 31, 2021. In January 2021, the Company issued convertible notes with a principal amount of $9,031,480.

The Company evaluated the Convertible Notes and determined that the Mandatory Conversion feature, Optional Conversion 1 feature and Change in Control meet the definition of an embedded derivative liability that is required to be bifurcated from the host instrument and measured at fair value. The fair value of the derivative liability for the convertible notes issued in January 2021 was $722,518.

The Company amortized the debt issuance costs of $256,212 and the debt discount from of the initial value of the derivative liability of $1,982,594 over the term of the Convertible Notes using the effective interest method. The debt issuance costs and debt discount amortization expense for the three months ended March 31, 2021 was $613,770 and is included in interest expense in the accompanying statements of operations. The interest expense at 6% of the Convertible Notes’ principal amount for the three months ended March 31, 2021 was $217,593. The effective interest rate during the three months ended March 31, 2021 was 25%. The unamortized debt issuance costs and debt discount on the Convertible Notes as of December 31, 2020, were $116,636 and $2,383,986, respectively.

The Company completed an IPO on February 11, 2021 which triggered the mandatory conversion of all the outstanding Convertible Notes principal plus accrued interest into shares of common stock (Note 10). Upon conversion of the Convertible Notes, the outstanding Convertible Notes principal plus accrued interest thereon, net of unamortized debt discounts totaling $30,252,056 was derecognized into stockholders’ deficit.

10. Series A Redeemable Convertible Preferred Stock and Stockholders’ Deficit

Issuances of Common Stock

On February 11, 2021, the Company completed its IPO, pursuant to which it issued and sold 7,441,650 shares of its common stock at a public offering price of $17.00 per share, resulting in net proceeds of $115,191,259, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of the 175,137,398 outstanding shares of the Company’s Redeemable Convertible Preferred Stock automatically converted into 10,144,052 shares of common stock after giving effect to the reverse stock split, and all of the outstanding Convertible Notes principal and accrued but unpaid interest thereon of $31,272,224 converted to 3,669,010 shares of common stock . Upon completion of the offering on February 11, 2021, the Company’s authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.

In January 2021, 145,000 warrants were exercised at an exercise price of $0.01 and 145,000 shares of Series A redeemable convertible stock were issued and then converted into common stock upon the closing of the IPO. The remaining outstanding warrants outstanding as of December 31, 2020 were exercised and settled in January 2021 with 2,896 shares of common stock issued in a cashless exercise.

11. Stock-Based Compensation

During January 2017, the Company adopted the 2017 Equity Incentive Plan (the “2017 Plan”), which provides for granting of restricted stock, options to purchase shares of common stock and other awards to employees, directors and consultants. In March 2017, the Company amended the 2017 Plan to increase the number of available shares to 660,838. In June 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”) which provides for granting of restricted stock, options to purchase shares of common stock, and other awards to employees, directors and consultants, and reserved 1,741,770 shares for this purpose. The 2018 Plan was amended in July 2018 to increase the number of available shares to 1,809,143. In February 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 2,757,556 shares under the plan. No further shares will be issued under the 2017 and 2018 plans. There are 1,586,365 shares available for issuance under the 2021 plan.

The number of options to be granted under the 2021 Plan, the option exercise prices, and other terms of the options are determined by the Board of Directors in accordance with the terms of the 2021 Plan. Generally, stock options are granted at fair value, become exercisable over a period of one to four years, expire in ten years or less and are subject to the employee’s continued employment.

Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended March 31, 2021 and 2020:


	2021		2020
Research and development expenses	$	204,330	$	82,743
General and administrative expenses		993,114		236,219

Total stock-based compensation expense	$	1,197,444	$	318,962

The following is a summary of option activity under the Company’s Stock Option Plans:


	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (millions)
Outstanding as of January 1, 2021		2,233,185		$	3.52
Granted		1,170,891			17.00
Exercised		(65,013	)		4.56
Cancelled		(772	)		4.31
Forfeited		(192,243	)		4.83

Outstanding as of March 31, 2021		3,146,048		$	8.44		7.98	$	33.5

Vested or expected to vest as of March 31, 2021		3,146,048		$	8.44		7.98	$	33.5
Exercisable as of March 31, 2021		1,730,292		$	3.18		6.64	$	27.5
Shares unvested as of March 31, 2021		1,415,786		$	14.86		9.63	$	6.0

The weighted average fair value of the options granted during the three months ended March 31, 2021 and 2020 was $11.64 and $4.04, respectively. The options were valued using the Black-Scholes option-pricing model for the three months ended March 31, 2021 and 2020 with the following assumptions:


	2021	2020
Expected volatility	79.8% to 81.0%	100%
Risk-free interest rate	0.6% to 0.7%	0.7% to 0.74%
Expected dividend yield	0%	0%
Expected term	5.5 to 6.0 years	5.3 to 6.0 years

The total fair value of stock options vested during the three months ended March 31, 2021 and 2020 was approximately $0.8 million, and $0.4 million, respectively. The intrinsic value of stock options exercised for the three months ended March 31, 2021 and 2020 was approximately $232,268 and $0, respectively.

As of March 31, 2021, there was $15.3 million of total unrecognized compensation expense related to unvested options that will be recognized over a weighted average period of 3.38 years.

12. Net Loss Per Share Attributable to Common Stockholders

Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company’s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and warrants and the if-converted method is used to determine the dilutive effect of the Company’s redeemable convertible preferred stock and Convertible Notes. For the three months ended March 31, 2021 and 2020, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options and shares of redeemable convertible preferred stock were excluded from the calculation of diluted loss per share. Under the if converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive. The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2021 and 2020:


	March 31, 2021			March 31, 2020
Net loss	$	(8,546,551	)	$	(6,315,508	)
Accumulated dividends on Redeemable Convertible Preferred Stock		(377,562	)		(815,516	)

Net loss attributable to common stockholders	$	(8,924,113	)	$	(7,131,024	)

Basic and diluted net loss per common share	$	(0.71	)	$	(5.68	)
Basic and diluted weighted average common shares outstanding		12,633,123			1,254,681

The following potentially dilutive securities outstanding at March 31, 2021 and 2020 have been excluded from the computation of diluted weighted average common shares outstanding, as the effect would be anti-dilutive:


	March 31, 2021		March 31, 2020
Stock options		3,146,048		2,242,145
Redeemable convertible preferred stock		4,733,929		10,135,735
Convertible debt		2,059,100		—
Warrants		611		14,480
Total		9,939,688		14,374,460

Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the two-class method.

13. Income Taxes

The Company has not recorded any tax provision or benefit for the three months ended March 31, 2021. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards, and research and development credits is not more-likely-than-not to be realized at March 31, 2021 and December 31, 2021. The effective tax rate for the three months ended March 31, 2021 and 2020 is 0%.

The Company has not recorded any accruals related to uncertain tax positions as of March 31, 2021 and December 31, 2020. We file U.S. and state income tax returns in jurisdictions with varying statutes of limitations. The 2016 through 2019 tax years remain subject to examination by federal and state tax authorities.

14. Employee Benefit Plan

The Company has a defined contribution plan under the Internal Revenue Code Section 401(k). The plan covers all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company may contribute a matching contribution at its discretion. During the three months ended March 31, 2021 and 2020, the Company made contributions of $40,233 and $32,749, respectively, to the plan.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our final prospectus for our initial public offering filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, or the Securities Act, on February 11, 2021 (the “Prospectus”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Investors and others should note that we routinely use the Investor Relations section of our website to announce material information to investors and the marketplace. While not all of the information that we post on the Investor Relations section of our website is of a material nature, some information could be deemed to be material. Accordingly, we encourage investors, the media, and others interested in us to review the information that it shares on the Investor Relations section of our website, www.neximmune.com.

Overview

We are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

We were incorporated under the laws of the State of Delaware on June 7, 2011. In June 2011, we exclusively licensed the core AIM technology from The Johns Hopkins University, or Johns Hopkins. See “Business—Johns Hopkins License Agreement” for information about this license.

To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, identifying and developing product candidates, enhancing our intellectual property portfolio, undertaking research, conducting preclinical studies and clinical trials, and securing manufacturing for our development programs. We do not have any products approved for sale and have not generated any revenue from product sales.

To date, we have funded our operations primarily with proceeds from private placement of convertible preferred stock, our convertible promissory notes and the IPO. In February 2021, we completed the IPO and issued and sold an aggregate 7,441,650 shares of common stock, which included 970,650 shares of our common stock issued pursuant to the underwriters’ option to purchase additional shares, at a public offering price of $17.00 per share, for net proceeds of $114.6 million after deducting underwriting discounts and commissions and other offering costs.

We have incurred significant operating losses since our inception, which are mainly attributed to research and development costs and employee payroll expense included in general and administrative expenses. As of March 31, 2021, we had an accumulated deficit of $85.2 million Our operating losses may fluctuate significantly from quarter-to-quarter and year-to-year as a result of several factors, including the timing of our preclinical studies and clinical trials and our expenditures related to other research and development activities. We expect to continue to incur operating losses for the foreseeable future. We anticipate these losses will increase substantially as we advance our product candidates through preclinical and clinical development, develop additional product candidates and seek regulatory approvals for our product candidates. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more product candidates. In addition, if we obtain marketing approval for any product candidate, we expect to incur pre-commercialization expenses and significant commercialization expenses related to marketing, sales, manufacturing and distribution We may also incur expenses in connection with the in-licensing of additional product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations, compliance and other expenses that we did not incur as a private company.

As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through public or private equity offerings, debt financings, collaborations and licensing arrangements or other capital sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

As of March 31, 2021, we had cash and cash equivalents of $118.1 million.

Components of our Results of Operations

Revenue

We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all.

Research and Development Expenses

To date, our research and development expenses, have related primarily to development of NEXI-001 and NEXI-002, preclinical studies and other preclinical activities related to our portfolio. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses also include the accrual of minimum royalties under our Johns Hopkins license.

Research and development expenses include:

•

salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved in research and development efforts;

•

external research and development expenses incurred under agreements with contract research organizations, or CROs, and consultants to conduct our preclinical, toxicology and other preclinical studies;

•

laboratory supplies;

•

costs related to manufacturing product candidates, including fees paid to third-party manufacturers and raw material suppliers;

•

license fees and research funding; and

•

facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance, equipment and other supplies.

Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. We outsource a substantial portion of our clinical trial activities, utilizing external entities such as CROs, independent clinical investigators and other third-party service providers to assist us with the execution of our clinical trials. We also expect to incur additional expenses related to milestone and royalty payments payable to Johns Hopkins.

We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and seek to discover and develop new product candidates. Due to the inherently unpredictable nature of preclinical and clinical development, we cannot determine with certainty the timing of the initiation, duration or costs of future clinical trials and preclinical studies of product candidates. Clinical and preclinical development timelines, the probability of success and the amount of development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates and development programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate’s commercial potential. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Our future clinical development costs may vary significantly based on factors such as:

•

per-patient trial costs;

•

the number of trials required for regulatory approval;

•

the number of sites included in the trials;

•

the countries in which the trials are conducted;

•

the length of time required to enroll eligible patients;

•

the number of patients that participate in the trials;

•

the number of doses that patients receive;

•

the drop-out or discontinuation rates of patients;

•

potential additional safety monitoring requested by regulatory agencies;

•

the duration of patient participation in the trials and follow-up;

•

the phase of development of the product candidate; and

•

the efficacy and safety profile of the product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in our executive, finance and other administrative functions. Other significant costs include facility related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and insurance costs. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, pre-commercialization and, if any product candidates receive marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company.

Interest Income

Interest income consists of interest earned on our cash equivalents during the period.

Interest Expense

Interest expense consists of interest accrued on the convertible notes and interest recognized upon the amortization of the beneficial conversion feature, debt issuance costs and bifurcated derivative liability.

Change in Fair Value of Derivative Liability

The change in fair value of derivative liability consists entirely of the mark-to-market adjustment of the bifurcated derivative liability related to the convertible notes. As a result of our IPO, the derivative liability was settled.

Results of Operations

Comparison of the Three Months Ended March 31, 2021 and 2020

The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020:


	For the three months ended March 31,
	2021			2020			Change
	(in thousands)
Operating expenses
Research and development	$	6,013		$	4,272		$	1,741
General and administrative		4,057			2,089			1,969

Total operating expenses		10,070			6,361			3,709

Loss from operations		(10,070	)		(6,361	)		(3,709	)

Other expense (income):
Interest income		4			19			(15	)
Interest expense		(904	)		(1	)		(903	)
Change in fair value of derivative liability		2,425			—			2,425
Other income (expense)		(1	)		27			(28	)

Other expense (income)		1,524			45			1,479

Net loss	$	(8,546	)	$	(6,316)		$	(2,230	)

Research and Development Expenses. Research and development expenses were $6.0 and $4.3 million for the three months ended March 31, 2021 and 2020, respectively. The increase of $1.7 million was due primarily to increases of $1.1 million for clinical trial expenses and increases to salary and benefits of $0.5 million resulting from increased headcount. We have not historically tracked internal research and development expenses by product candidate.

General and Administrative Expenses. General and administrative expenses were $4.1 and $2.1 million for the three months ended March 31, 2021 and 2020, respectively. The increase of $2.0 was due primarily to increases of $0.8 million in stock compensation expense following the IPO, an increase of $0.8 million in professional fees and an increase in insurance of $0.4 million for Directors and Officers insurance.

Interest Expense. Interest expense was $0.9 million and $0.0 million for the three months ended March 31, 2021 and 2020, respectively. The increase is due to the issuance of convertible debt during the period from April 2020 into January 2021.

Change in Fair Value of Derivative Liability. The change in fair value of derivative liability was $2.4 and $0.0 million for the three months ended March 31, 2021 and 2020, respectively. The increase reflected the remeasurement of the derivative liability immediately before the conversion of the convertible notes into shares of common stock upon the completion of the IPO in February 2021. Following the IPO there are no derivative instruments.

Liquidity and Capital Resources

We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of March 31, 2021, we had cash and cash equivalents of $118.1 million.

Sources of Liquidity

To date, we have financed our operations principally through private placements of our redeemable convertible preferred stock, our convertible promissory notes and the IPO.

Series A Preferred Stock Financing

In December 2017 through August 2018, we issued an aggregate of 121,735,303 shares of our Series A Redeemable Convertible Preferred Stock at a purchase price of $0.2951 per share for aggregate consideration of $25.0 million plus conversion of convertible notes.

In January 2019 and February 2019, we issued an aggregate of 22,047,361 shares of our Series A-2 Preferred Stock at a purchase price of $0.3523 per share for aggregate consideration of $7.8 million.

In November 2019 and December 2019, we issued an aggregate of 31,209,734 shares of our Series A-3 Preferred Stock at a purchase price of $0.3523 per share for aggregate consideration of $11.0 million.

Convertible Note Financing

From April 2020 through December 31, 2020, we issued $21,618,286 aggregate principal amount of convertible notes, which bore interest at the rate of 6% per annum and had a scheduled maturity date in April 2021.

In January 2021, we issued an additional $9,031,480 aggregate principal amount of convertible notes, which bore interest at the rate of 6% per annum and had a scheduled maturity date in April 2021.

Paycheck Protection Program Loan

On April 23, 2020, we entered into an unsecured loan agreement with JPMorgan Chase Bank, or Chase, under the terms of which Chase loaned us $843,619, or the PPP Loan, pursuant to the Paycheck Protection Program, or PPP, under the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act. In accordance with the requirements of the CARES Act, we have used the proceeds primarily for payroll costs and other eligible expenses. The PPP Loan has a maturity date of April 23, 2022 and accrues interest at an annual rate of 0.98%. Interest and principal payments are deferred for the first six months of the loan. Thereafter, monthly interest and principal payments are due until the loan is fully satisfied. The promissory note evidencing the PPP Loan contains customary events of default resulting from, among other things, default in the payments. The use of loan proceeds must be for payroll costs, payment of interest on covered mortgage obligations, rent and utility costs over either an eight-week or 24-week period, at our option, following our receipt of the loan proceeds. We elected to use the proceeds over a 24-week period. We treat the PPP loan as debt under ASC 470, Debt. The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. We submitted the PPP Loan forgiveness application in March 2021. Although we believe it is probable that the PPP Loan will be forgiven, we cannot provide any objective assurance that we will obtain forgiveness in whole or in part.

Initial Public Offering

In February 2021, we completed the IPO and issued and sold an aggregate 7,441,650 shares of common stock, which included 970,650 shares of our common stock issued pursuant to the underwriters’ option to purchase additional shares, at a public offering price of $17.00 per share, for net proceeds of $114.6 million after deducting underwriting discounts and commissions and other offering costs.

Cash Flows

The following table sets forth a summary of the net cash flow activity for the three months ended March 31, 2021 and 2020:


	2021			2020
	(in thousands)
Net cash provided by (used in):
Operating activities	$	(11,155)		$	(6,510)
Investing activities		(581	)		758
Financing activities		124,808			(5	)

Net (decrease) increase in cash, cash equivalents and restricted cash	$	113,072		$	5,757

Operating Activities

Net cash used in operating activities was $11.2 million and $6.5 million for the three months ended March 31, 2021 and 2020, respectively. The net cash used in operating activities for the three months ended March 31, 2021 was primarily due to our net loss of $8.5 million, resulting from R&D expenditures of $6.0 million as we ramp up our clinical program and $4.1 million of administrative expenses for public company expenses, salary and related expenses and professional fees. In addition, there were decreases of $2.5 million in working capital changes.

The net cash used in operating activities for the three months ended March 31, 2020 was primarily due to our net loss of $6.3 million, consisting of $4.2 million for R&D expenses primarily in pre-clinical research expenses and manufacturing as we prepared for our clinical program, and $2.1 million in administrative expenses for salary and related expenses and professional fees. In addition, there were decreases of $0.7 million in working capital changes.

Investing Activities

Net cash used in investing activities was $0.6 million for the three months ended March 31, 2021 resulting from purchases of property and equipment. Net cash provided by investing activities of $0.8 million for the three months ended March 31, 2020 was primarily due to maturities of available-for-sale marketable securities of $1.0 million, partially offset by the purchase of property and equipment for $0.2 million.

Financing Activities

Net cash provided by financing activities was $124.8 million for the three months ended March 31, 2021 primarily due to the net proceeds of $115.5 million from the IPO and $9.0 million from the issuance of convertible debt.

Funding Requirements

We believe that our existing cash and cash equivalents, will be sufficient to meet our anticipated cash requirements through the second quarter of 2022. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.

Our future capital requirements will depend on many factors, including:

•

the initiation, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of NEXI-001 and NEXI-002 and any other future product candidates;

•

the number and characteristics of product candidates that we pursue;

•

the outcome, timing and costs of seeking regulatory approvals;

•

the cost of manufacturing NEXI-001 and NEXI-002 and future product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization;

•

the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;

•

the emergence of competing therapies and other adverse market developments;

•

the ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;

•

the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;

•

the extent to which we in-license or acquire other products and technologies; and

•

the costs of operating as a public company.

Until such time, if ever, as we can generate substantial product revenues to support our capital requirements, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other capital sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may need to relinquish valuable rights to our product candidates, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings as and when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 3, “Summary of significant accounting policies”, and in our Form 10K for the year ended December 31, 2020, we believe the following accounting policies and estimates to be most critical to the preparation of our financial statements.

Stock-Based Compensation Expense

Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. We estimate the fair value of equity awards using the Black-Scholes option pricing model and recognize forfeitures as they occur. Estimating the fair value of equity awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. See Note 3, “Summary of significant accounting policies” for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted for the three months ended March 31, 2021 and 2020.

Common stock valuations

We are required to estimate the fair value of the common stock underlying our equity awards when performing fair value calculations. The fair value of the common stock underlying our equity awards was determined on each grant date by our board of directors, taking into account input from management and independent third-party valuation analyses. All options to purchase shares of our common stock are intended to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant. In the absence of a public trading market for our common stock, on each grant date we develop an estimate of the fair value of our common stock in order to determine an exercise price for the option grants. Our determinations of the fair value of our common stock were made using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide: Valuation of Privately Held Company Equity Securities Issued as Compensation, or the Practice Aid.

Our board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of our common stock, including:

•

valuations of our common stock performed with the assistance of independent third-party valuation specialists;

•

current and potential strategic relationships and licenses;

•

our stage of development and business strategy, including the status of research and development efforts of our product candidates, and the material risks related to our business and industry;

•

our results of operations and financial position, including our levels of available capital resources;

•

the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies;

•

the lack of marketability of our common stock as a private company;

•

the prices of preferred stock sold to investors in arm’s length transactions and the rights, preferences and privileges of our preferred stock relative to those of our common stock;

•

the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a sale of our company, given prevailing market conditions;

•

trends and developments in our industry; and

•

external market conditions affecting the life sciences and biotechnology industry sectors.

The Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our future operations, discounting to the present value with an appropriate risk-adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology was considered in our valuations.

The various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock in accordance with the Practice Aid include the following:

Option Pricing Method, or OPM. Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options.

Probability-Weighted Expected Return Method, or PWERM. The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each equity class.

In determining the fair value of our common stock underlying stock option grants for the years ended December 31, 2020 and 2019, we estimated the enterprise value of our business using the back-solve method and the OPM to allocate enterprise value. The back-solve method is a market approach that assigns an implied enterprise value based on the most recent round of funding or investment and allows for the incorporation of the implied future benefits and risks of the investment decision assigned by an outside investor. We believed the OPM was the most appropriate method given the expectation of various potential liquidity outcomes and the difficulty of selecting and supporting appropriate enterprise values given our early stage of development.

The determination of the fair value of our common stock after our IPO on February 11, 2021 is determined by the closing price our common stock on the date of grant.

Other Company Information

Net Operating Loss and Research and Development Carryforwards and Other Income Tax Information

At December 31, 2020, we had federal and state net operating loss carryforwards of $69.1 million. As of December 31, 2020, we also had federal research credit carryforwards of $0.3 million. Approximately $10.5 million of the federal NOL was generated prior to 2018 and will expire in increments through 2037 beginning in 2035, while the remaining $58.6 million will be carried forward indefinitely. The state NOL will expire in increments through 2037, beginning expiring in 2035. The federal research and development tax credit carryforwards, if not utilized, will expire beginning in 2037.

We believe that it is more likely than not that we will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2020. Management reevaluates the positive and negative evidence at each reporting period.

We have not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation due to the complexity and cost associated with such a study and the fact that there may be additional such ownership changes in the future. Pursuant to Sections 382 and 383 of the Internal Revenue Code, annual use of our net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.

Emerging Growth Company and Smaller Reporting Company Status

We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth company until the earlier of (1) December 31, 2026, (2) the last day of the fiscal year in which we have total annual gross revenues of at least $1.07 billion, (3) the date on which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company,

•

we may present only two years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this filing.

•

we may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act;

•

we may provide reduced disclosure about our executive compensation arrangements; and

•

we may not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements.

We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this filing is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. Until the date that we are no longer an emerging growth company or affirmatively and irrevocably opt out of the exemption provided by Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which we will adopt the recently issued accounting standard.

We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of the IPO was less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. After the IPO we may continue to be a smaller reporting company if either (1) the market value of our stock held by non-affiliates is less than $250.0 million or (2) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Quarterly Report on Form 10-Q and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

Recently Issued and Adopted Accounting Pronouncements

A description of recently issued and adopted accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3, “Summary of significant accounting policies”.

Off-Balance Sheet Arrangements

During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.

Item 3. Quantitative and qualitative disclosures about market risk.

Not applicable

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2021. Based on the evaluation of our disclosure controls and procedures as of March 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

Previously Identified Material Weakness

In preparation for our initial public offering, we identified a material weakness in our internal control over financial reporting related to our control environment. Specifically, we have determined that we have not maintained adequate formal accounting policies, processes and controls related to complex transactions as a result of a lack of finance and accounting staff with the appropriate GAAP technical expertise needed to identify, evaluate and account for complex and non-routine transactions. We also determined that we have not maintained sufficient staffing or written policies and procedures for accounting and financial reporting, which contributed to the lack of a formalized process or controls for management’s timely review and approval of financial information. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis.

More specifically, we have determined that our financial statement close process includes significant control gaps mainly driven by the small size of our accounting and finance staff and, as a result, a significant lack of appropriate segregation of duties. We also determined that we have not maintained sufficient staffing or written policies and procedures for accounting and financial reporting, which contributed to the lack of a formalized process or controls for management’s timely review and approval of financial information.

The process of designing and implementing an effective accounting and financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain an accounting and financial reporting system that is adequate to satisfy our reporting obligations. As we continue to evaluate and take actions to improve our internal control over financial reporting, we may determine to take additional actions to address control deficiencies or determine to modify certain of the remediation measures described above. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to remediate the material weakness we have identified or avoid potential future material weaknesses.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period covered by this filing that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Set forth below is information regarding shares of equity securities sold, and options granted, by us during the three months ended March 31, 2021 that were not registered under the Securities Act.

Recent Sales of Unregistered Equity Securities

During the period between January 1, 2021 and March 31, 2021, we issued to certain of our employees, consultants and directors, options to purchase an aggregate of 1,170,891 shares of our common stock at a weighted-average exercise price of $17 per share. We deemed these issuances to be exempt from registration under the Securities Act either in reliance on Rule 701 of the Securities Act as sales and offers under compensatory benefit plans and contracts relating to compensation in compliance with Rule 701, or in reliance on Section 4(a)(2), as transactions by an issuer not involving a public offering. All recipients either received adequate information about our company or had access, through employment or other relationships, to such information. No underwriters were involved in the foregoing issuances of securities. We filed a registration statement on Form S-8 under the Securities Act on Febuary 25, 2021 to register all of the shares of our common stock subject to outstanding options and all shares of our common stock otherwise issuable pursuant to our equity compensation plan.

In January 2021, we issued $9,031,480 aggregate principal amount of convertible notes to certain investors. We deemed this transaction to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) as a transaction by an issuer not involving a public offering.

Use of Proceeds from Initial Public Offering

In February 2021, we completed the IPO and issued and sold an aggregate 7,441,650 shares of common stock, which included 970,650 shares of our common stock issued pursuant to the underwriters’ option to purchase additional shares, at a public offering price of $17.00 per share, for net proceeds of $114.8 million after deducting underwriting discounts and commissions and other offering costs.

The offer and sale of all of the shares of our common stock in our initial public offering of common stock, or the IPO, was effected through a Registration Statement on Form S-1 (File No. 333- 252220) that was declared effective by the SEC on February 11, 2021.

None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates. We have invested the net proceeds from the IPO in a money market fund. There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 11, 2021.

We have invested the net proceeds from the IPO in a variety of capital preservation investments in government cash management fund. There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February 16, 2021.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.


Exhibit Number		Description

3.1		Form of Sixth Amended and Restated Certificate of Incorporation. (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-40045) filed with the SEC on February 18, 2021)

3.2		Restated Bylaws of NexImmune, Inc. (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K (File No. 001-40045) filed with the SEC on February 18, 2021)

10.1		Form of Indemnification Agreement. (incorporated by reference to Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.2.1		2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.2.2		Form of Stock Option Agreement under the 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.2.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.3.1		2018 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.3.2		Form of Stock Option Agreement under the 2018 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.4.1		2021 Equity Incentive Plan, (incorporated by reference to Exhibit 10.4.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.4.2		Form of Stock Option Agreement under the 2021 Equity Incentive Plan, incorporated by reference to Exhibit 10.4.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.5		Employment Agreement, by and between the Registrant and Scott Carmer, dated February 3, 2021 (incorporated by reference to Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)


10.6		Employment Agreement, by and between the Registrant and John Trainer, dated January 6, 2020 (incorporated by reference to Exhibit 10.6 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.7		Employment Agreement, by and between the Registrant and Jerome Zeldis, M.D., Ph.D., dated January 4, 2021 (incorporated by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.8		Employment Agreement, by and between the Registrant and Kristi Jones, dated February 27, 2017 (incorporated by reference to Exhibit 10.8 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.9		Employment Agreement, by and between the Registrant and Robert Knight, M.D., dated January 6, 2021(incorporated by reference to Exhibit 10.9 of the Registrant’s Registration Statement on Form S-1 (File No. 333-252220) filed with the SEC on February 8, 2021)

10.10*		Non-Employee Director Compensation Policy

31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Company Name

Date: May 17, 2021	By:	/s/ John Trainer
		John Trainer, M.B.A.
		Chief Financial Officer

Date: May 17, 2021	By:	/s/ Scott Carmer
		Scott Carmer
		President and Chief Executive Officer

EX-10.10 2 d277349dex1010.htm EX-10.10 EX-10.10

Exhibit 10.10

NexImmune, Inc.

Non-Employee Director Compensation Policy

The Board of Directors of NexImmune, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”). The Policy is apply to all non-employee directors of the Company. In exchange for their service, each director will be eligible for the following annual cash compensation, cash compensation for service on the Committees of the Board of Directors and equity compensation, including an initial equity awards and annual equity awards, as set forth in this Policy:

Application

This Policy shall apply to each director of the Company who is not an employee of, or consultant to, the Company or any Affiliate. “Affiliate” means a corporation which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended.

Annual Cash Compensation

•

Each non-employee director will receive an annual cash retainer of $35,000 per year.

•

The non-employee Chair of the board will receive additional annual cash compensation of $30,000 per year.

Cash Compensation for Committee Service

•

The Chair of the Audit Committee will receive additional annual cash compensation of $15,000 per year. Each member of the Audit Committee will receive additional annual cash compensation of $7,500 per year.

•

The Chair of the Compensation Committee will receive additional annual cash compensation of $10,000 per year. Each member of the Compensation Committee will receive additional annual cash compensation of $5,000 per year.

•

The Chair of the Nominating and Corporate Governance Committee will receive additional annual cash compensation of $8,000 per year. Each member of the Nominating and Corporate Governance Committee will receive additional annual cash compensation of $4,000 per year.

•

The Chair of the Science and Technology Committee will receive additional annual cash compensation of $10,000 per year. Each member of the Science and Technology Committee will receive additional annual cash compensation of $5,000 per year.

•

The Chair of the Technical Operations Committee will receive additional annual cash compensation of $10,000 per year. Each member of the Technical Operations Committee will receive additional annual cash compensation of $5,000 per year.

Equity Awards

•

On the date of each annual stockholder’s meeting, the Company will grant to each director an annual option award with a cash value equal to $85,400. The annual option award will fully vest on the first anniversary of the grant date.

•

When a new director joins the Board of Directors, the Company will grant to the new director an initial option award to acquire shares of the Company’s Common Stock with a cash value equal to two times the cash value of the annual award. The Company will award the initial option award at the meeting of the Board of Directors on which the new director first takes their seat. The initial option award will vest in 36 equal monthly installments over the following three-year period. A director that receives an initial option award will not receive an annual option award in the year in which the director joins the Board of Directors.

•

The number of shares covered by each option award to a director will be determined as follows: The option value will be determined based on the Black-Scholes value of an option to purchase a share of the Company’s Common Stock, calculated using its closing price on the day prior to the grant date and consistent with the calculation method used by the Company to report the value of option awards in its public disclosures. The resulting option value will be divided into the target value of the option award. If the result is not a whole number of shares, the number of shares will be rounded down to the nearest whole share.

Summary Compensation Table


Committee	Chair (Annual)	Member (Annual)	EQUITY
BOARD MEMBER		$35,000	(ANNUAL GRANT) $85,400 (1) (APPOINTMENT GRANT) 2X Cash Value of Annual Grant (2)

NON-EMPLOYEE CHAIRMAN OF THE BOARD	$30,000

AUDIT	$15,000	$7,500

COMPENSATION	$10,000	$5,000

NOMINATING & GOVERNANCE	$8,000	$4,000

SCIENCE & TECHNOLOGY COMMITTEE	$10,000	$5,000

TECHNICAL OPERATIONS COMMITTEE	$10,000	$5,000

(1)	Annual option award will fully vest on the first anniversary of the grant date.

(2)

Appointment Grant awarded at the BOD meeting on which the new director first takes their seat and will vest in 36 equal monthly installments over the following three-year period. A director that receives an initial option award will not also receive an annual option award in the year in which the director joins the BOD.

(3)	Voluntary Deferral of Cash Compensation – Refer to policy (Pg.3)

Voluntary Deferral of Cash Compensation

•

The Company will provide the directors with the ability to receive an option award in lieu of the cash compensation payable in a calendar year. The option award will have a target value equal to the director’s annual cash compensation and the number of shares subject to the option award will be determined as set forth above. The Company will make the option award in lieu of cash compensation at the annual stockholder’s meeting. The option award will be fully vested on the grant date.

•

A director that desires to receive an option award in lieu of the cash compensation payable in a calendar year must deliver to the Company’s General Counsel an election in writing on or after October 15 and on or before December 15 of the calendar year preceding the calendar year in which the cash compensation is due to be paid. If the Company does not receive a written election during this period, the Company will pay the director the scheduled cash compensation.

•

A director must make a new election to receive an option award in lieu of cash compensation for each calendar year. An election to receive an option award in lieu of cash compensation in effect for a prior calendar year will not remain in effect for any subsequent calendar year.

Amendments

The Compensation Committee or the Board of Directors shall review this Policy from time to time to assess whether any amendments in the type and amount of compensation provided herein should be adjusted in order to fulfill the objectives of this Policy.

EX-31.1 3 d277349dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION UNDER SECTION 302

I, Scott Carmer, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of NexImmune, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 4 d277349dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION UNDER SECTION 302

I, John Trainer, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of NexImmune, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 5 d277349dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NexImmune, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge that:

The Quarterly Report for the period ended March 31, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-32.2 6 d277349dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION UNDER SECTION 906

EX-101.INS 7 nexi-20210331.xml XBRL INSTANCE DOCUMENT 0001538210 2021-01-01 2021-03-31 0001538210 2021-03-31 0001538210 2020-12-31 0001538210 2020-01-01 2020-03-31 0001538210 2018-06-30 0001538210 2021-02-11 0001538210 2021-01-31 0001538210 2013-05-23 2013-05-23 0001538210 2020-03-31 0001538210 2019-12-31 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-03-31 0001538210 nexi:TwoThousandTwentyOneEquityIncentivePlanMember srt:MinimumMember 2021-01-01 2021-03-31 0001538210 nexi:TwoThousandTwentyOneEquityIncentivePlanMember srt:MaximumMember 2021-01-01 2021-03-31 0001538210 nexi:TwoThousandTwentyOneEquityIncentivePlanMember 2021-01-01 2021-03-31 0001538210 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001538210 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001538210 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001538210 us-gaap:RedeemableConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001538210 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-03-31 0001538210 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001538210 nexi:MarylandBiotechnologyCenterMember nexi:TranslationalResearchAwardAgreementMember 2021-01-01 2021-03-31 0001538210 nexi:JohnsHopkinsUniversityMember nexi:ExclusiveLicenseAgreementMember 2021-01-01 2021-03-31 0001538210 srt:MinimumMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001538210 us-gaap:ConvertibleDebtMember 2021-01-01 2021-03-31 0001538210 nexi:PaycheckProtectionProgramLoanMember 2021-01-01 2021-03-31 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001538210 nexi:SeriesATwoRedeemableConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001538210 nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001538210 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001538210 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001538210 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001538210 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001538210 srt:MinimumMember 2021-01-01 2021-03-31 0001538210 srt:MaximumMember 2021-01-01 2021-03-31 0001538210 nexi:SeriesATwoRedeemableConvertiblePreferredStockMember 2021-03-31 0001538210 nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember 2021-03-31 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2021-03-31 0001538210 nexi:LaboratoryEquipmentMember 2021-03-31 0001538210 nexi:ComputerEquipmentAndSoftwareMember 2021-03-31 0001538210 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001538210 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001538210 nexi:MarylandBiotechnologyCenterMember nexi:TranslationalResearchAwardAgreementMember 2021-03-31 0001538210 us-gaap:ConvertibleDebtMember 2021-03-31 0001538210 nexi:JohnsHopkinsUniversityMember nexi:ExclusiveLicenseAgreementMember 2021-03-31 0001538210 nexi:PaycheckProtectionProgramLoanMember 2021-03-31 0001538210 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-01-01 0001538210 us-gaap:AdditionalPaidInCapitalMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember nexi:MeasurementInputProbabilitiesOfConversionProvisionsMember srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember nexi:MeasurementInputProbabilitiesOfConversionProvisionsMember srt:MaximumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputSharePriceMember srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputSharePriceMember srt:MaximumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember nexi:MeasurementInputEstimatedTimingOfConversionMember srt:MinimumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember nexi:MeasurementInputEstimatedTimingOfConversionMember srt:MaximumMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 us-gaap:MeasurementInputExpectedTermMember us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueInputsLevel3Member 2021-01-01 0001538210 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-01-01 0001538210 us-gaap:ConvertibleDebtMember 2021-01-01 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2020-12-31 0001538210 nexi:SeriesATwoRedeemableConvertiblePreferredStockMember 2020-12-31 0001538210 nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember 2020-12-31 0001538210 nexi:LaboratoryEquipmentMember 2020-12-31 0001538210 nexi:ComputerEquipmentAndSoftwareMember 2020-12-31 0001538210 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001538210 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001538210 us-gaap:ConvertibleDebtMember 2020-12-31 0001538210 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001538210 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001538210 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001538210 us-gaap:RedeemableConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001538210 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-03-31 0001538210 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001538210 srt:MinimumMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001538210 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001538210 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001538210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001538210 srt:MinimumMember 2020-01-01 2020-03-31 0001538210 srt:MaximumMember 2020-01-01 2020-03-31 0001538210 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-02-11 0001538210 us-gaap:RedeemableConvertiblePreferredStockMember 2021-02-11 0001538210 nexi:MarylandBiotechnologyCenterMember nexi:TranslationalResearchAwardAgreementMember 2012-05-23 0001538210 nexi:MarylandBiotechnologyCenterMember nexi:TranslationalResearchAwardAgreementMember 2013-05-23 0001538210 nexi:MarylandBiotechnologyCenterMember nexi:TranslationalResearchAwardAgreementMember 2013-05-23 2013-05-23 0001538210 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-02-11 2021-02-11 0001538210 us-gaap:ConvertibleDebtMember 2021-02-11 2021-02-11 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2021-01-31 0001538210 us-gaap:ConvertibleDebtMember 2021-01-31 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2021-01-01 2021-01-31 0001538210 nexi:ExclusiveLicenseAgreementMember nexi:JohnsHopkinsUniversityMember 2017-01-01 2017-01-01 0001538210 nexi:ClinicalTrialMilestonesMember nexi:JohnsHopkinsUniversityMember nexi:ExclusiveLicenseAgreementMember 2017-01-01 2017-01-01 0001538210 nexi:TherapeuticFieldMember nexi:JohnsHopkinsUniversityMember nexi:ExclusiveLicenseAgreementMember 2017-01-01 2017-01-01 0001538210 nexi:RegulatoryAndCommercialMilestonesMember nexi:JohnsHopkinsUniversityMember nexi:ExclusiveLicenseAgreementMember 2017-01-01 2017-01-01 0001538210 nexi:NonclinicalFieldMember nexi:JohnsHopkinsUniversityMember nexi:ExclusiveLicenseAgreementMember 2017-01-01 2017-01-01 0001538210 nexi:PaycheckProtectionProgramLoanMember 2020-04-23 0001538210 us-gaap:OtherCurrentLiabilitiesMember 2020-04-23 0001538210 us-gaap:ConvertibleDebtMember 2020-04-01 2020-04-30 0001538210 us-gaap:ConvertibleDebtMember 2020-04-30 0001538210 us-gaap:ConvertibleDebtMember 2020-07-01 2020-07-31 0001538210 us-gaap:ConvertibleDebtMember 2020-07-31 0001538210 us-gaap:ConvertibleDebtMember 2020-09-01 2020-09-30 0001538210 nexi:TwoThousandSeventeenEquityIncentivePlanMember 2017-03-01 0001538210 nexi:TwoThousandEighteenEquityIncentivePlanMember 2018-06-01 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001538210 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001538210 us-gaap:CommonStockMember 2020-12-31 0001538210 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001538210 us-gaap:RetainedEarningsMember 2020-12-31 0001538210 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001538210 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001538210 us-gaap:AdditionalPaidInCapitalMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001538210 us-gaap:CommonStockMember 2021-03-31 0001538210 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001538210 us-gaap:RetainedEarningsMember 2021-03-31 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2019-12-31 0001538210 nexi:SeriesATwoRedeemableConvertiblePreferredStockMember 2019-12-31 0001538210 nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember 2019-12-31 0001538210 us-gaap:CommonStockMember 2019-12-31 0001538210 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001538210 us-gaap:RetainedEarningsMember 2019-12-31 0001538210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001538210 us-gaap:CommonStockMember 2020-03-31 0001538210 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001538210 us-gaap:RetainedEarningsMember 2020-03-31 0001538210 nexi:SeriesARedeemableConvertiblePreferredStockMember 2020-03-31 0001538210 nexi:SeriesATwoRedeemableConvertiblePreferredStockMember 2020-03-31 0001538210 nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember 2020-03-31 10-Q true false 2021-03-31 false --12-31 NexImmune, Inc. 0001538210 Yes false Non-accelerated Filer true true false 22579219 NASDAQ NEXI Common Stock 2021 Q1 Yes DE MD

<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">1. Nature of the business and basis of presentation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">NexImmune, Inc. (the “Company” or “NexImmune”), a Delaware corporation headquartered in Gaithersburg, Maryland, was incorporated on June 7, 2011. The Company is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are AIM nanoparticles, which act as synthetic dendritic cells. These AIM nanoparticles can be programmed to present specific antigens and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-stimulatory</div> signals to specific T cells, generating an immune response that can be directed toward any foreign substance or cell type in a patient’s body. The Company’s first two products, both for the treatment of different types of cancer, entered clinical trials in 2020. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The accompanying unaudited financial statements were prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). These financial statements should be read in conjunction with our audited financial statements and the accompanying notes to our financial statements contained in our Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-K</div> for the year ended December 31, 2020, as filed with the SEC on March 31, 2021. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our management’s opinion, the accompanying financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of March 31, 2021 and December 31, 2020, and our statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders’ deficit, and cash flows for the three month periods ended March 31, 2021 and 2020. Interim results are not necessarily indicative of results for an entire year. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

118102945

5031079

67500

4788019

3293858

122958464

8392437

3584412

2885260

23373

126566249

11301070

2406537

2760129

2842998

2603027

1702359

843619

7324267

11793397

6093154

27026798

11764

23529

4935

6104918

27055262

35047435

7685865

10887449

53620749

2258

126

205847571

8206938

-85388498

-77582005

120461331

-69374941

126566249

11301070

700000

2200000

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows. </div></div></div> <div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width: 64%;"></td><td style="width: 6%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 6%;;vertical-align:bottom;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">December 31, 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 64%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Cash and cash equivalents</div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">118,102,945</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,031,079</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 64%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">67,500</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">67,500</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 64%;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 64%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">118,170,445</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,098,579</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 64%;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

118170445

5098579

0.0001

250000000

22579219

1256609

22579219

1256609

0.0001

28384899

34061879

121735303

22047361

31209734

121735303

22047361

31209734

121735303

8683746

11699176

42314789

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4. Fair Value Measurements </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of March 31, 2021 and December 31, 2020 due to their short-term maturities. The Convertible Notes as discussed in Note 10 contain embedded derivative features that are required to be bifurcated and remeasured to fair value at each reporting period. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (“ASC 820”). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width: 4%;"> </td><td style="width: 10%;;text-align:left;;vertical-align:top;">Level 1 -</td><td style="width: 0%;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width: 4%;"> </td><td style="width: 10%;;text-align:left;;vertical-align:top;">Level 2 -</td><td style="width: 0%;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is determined by using inputs, other than Level 1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;;-webkit-margin-before: 0em;-webkit-margin-after: 0em;;font-weight: normal;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width: 4%;"> </td><td style="width: 10%;;text-align:left;;vertical-align:top;">Level 3 -</td><td style="width: 0%;;text-align:left;;vertical-align:top;"><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s derivative liability related to certain features embedded within the Company’s Convertible Notes as discussed in Note 10. The derivative is accounted for as a liability and remeasured to fair value as of each balance sheet date until the Convertible Note is settled or cancelled. The Convertible Notes were converted into shares of common stock upon the Company’s completion of the Initial Public Offering (“IPO”) on February 11, 2021. The related remeasurement adjustments are recognized in the accompanying statements of operations. </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the period ended March 31, 2021 and December 31, 2020 the Company did not have any transfers between levels. There were no Level 3 recurring fair value measurements as of March 31, 2021. The following table presents activity related to the Company’s fair value measurements categorized as Level 3 of the valuation hierarchy, valued on a recurring basis: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman"; width: 84%;"></td><td style="font-family: "times new roman"; width: 5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Balance as of December 31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,702,359</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of derivative liabilities issued</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; padding: 0px;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">722,518 </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="display:inline;">Reduction in</div> expense related to fair value changes in derivative liabilities</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,424,877</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 84%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March 31, 2021</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 84%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the derivative liability was determined using a binomial lattice model by calculating and comparing the fair value of the Convertible Notes with and without the embedded features. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key inputs into this valuation model are ( l) the probability of various events which result in conversion prior to the maturity of the Convertible Notes; (2) the estimated timing of conversion; (3) time period to maturity; (4) the fair value of the Company’s stock underlying the Convertible Notes within each scenario; (5) the expected volatility of the Company’s stock through the various events resulting in conversion; (6) the risk-adjusted discount rate; and (7) the Company’s stock dividend yield.</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The recurring Level 3 fair value measurements of the embedded features of the Convertible Notes issued in January 2021 include the following significant unobservable inputs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman"; width: 85%;"></td><td style="font-family: "times new roman"; width: 11%;;vertical-align:bottom;"></td><td style="font-family: "times new roman"; width: 0%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt; width: 85%;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Input</div></div></div></td><td style="padding-bottom: 1pt; width: 11%;;vertical-align:bottom;">  </td><td style="border-bottom: 1pt solid rgb(0, 0, 0); width: 0%;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Assumptions</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Probabilities of conversion provisions</div></div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">5%-50%</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Estimated timing of conversion (years)</div></td><td style="width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.13-0.31</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Time period to maturity (years)</div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;">0.31</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of the Company’s stock</div></div></td><td style="width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$0.45-$0.56</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock price volatility</div></div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">76-90%</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-adjusted discount rate</div></div></td><td style="width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; width: 0%;;text-align:center;;vertical-align:bottom;">25.56%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Dividend yield</div></div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;">0%</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><br/> <div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant changes to these assumptions would result in increases or decreases to the fair value of the derivative liability. There were no Convertible Notes issued after January 2021. Immediately before the conversion of the Convertible Notes on February 11, 2021, the derivative liability was remeasured to fair value which the Company concluded was immaterial. The derivative liability was remeasured to </div>zero.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All derivative instruments were eliminated following the conversion of the Convertible Notes on February 11, 2021. </div></div><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

The following table presents activity related to the Company’s fair value measurements categorized as Level 3 of the valuation hierarchy, valued on a recurring basis:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman"; width: 84%;"></td><td style="font-family: "times new roman"; width: 5%;;vertical-align:bottom;"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Balance as of December 31, 2020</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,702,359</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of derivative liabilities issued</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; padding: 0px;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">722,518 </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="display:inline;">Reduction in</div> expense related to fair value changes in derivative liabilities</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,424,877</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 84%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 84%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March 31, 2021</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 84%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6012608

4272167

4057592

2088401

10070200

6360568

-10070200

-6360568

3613

18684

904119

989

2424877

-722

27365

1523649

45060

-8546551

-6315508

815516

377562

-8924113

-7131024

-0.71

-5.68

12633123

1254681

-8546551

-6316014

1702359

722518

-2424877

500

5000

0.45

0.56

7600

9000

2556

0.13

0.31

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5. Prepaid Expenses and Other Current Assets </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Prepaid expenses and other current assets consist of the following at March 31, 2021 and December 31, 2020: <br/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 72%;"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid research and development expenses</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,922,643</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,894,785</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid maintenance agreements</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">113,059</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">144,575</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid insurance</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2,608,493</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">98,421</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid other</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">143,824</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">124,929</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred financing costs</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">952,633</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">78,515</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255); width: 72%;;vertical-align:top;"> </td><td style="background-color: rgb(255, 255, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">4,788,019</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(255, 255, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,293,858</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;width:;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Prepaid expenses and other current assets consist of the following at March 31, 2021 and December 31, 2020: <br/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 72%;"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px;"> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid research and development expenses</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,922,643</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,894,785</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid maintenance agreements</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">113,059</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">144,575</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid insurance</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2,608,493</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">98,421</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid other</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">143,824</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">124,929</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Deferred financing costs</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">952,633</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">78,515</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255); width: 72%;;vertical-align:top;"> </td><td style="background-color: rgb(255, 255, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">4,788,019</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="background-color: rgb(255, 255, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,293,858</div></td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;width:;"> </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;">  </td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;;width:;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2608493

98421

143824

124929

952633

78515

174331

143518

1922643 1894785 113059 144575

464

-398

1197444

318962

903919

-2424877

2446793

929007

-645847

-191877

633307

463090

-11155532

-6510424

581228

241519

494

999780

-580764

758317

5212

4832

297083

124808162

-4832

113071866

-4097908

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6. Property and Equipment </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following at March 31, 2021 and December 31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 73%;"></td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"></td><td style="font-family: "times new roman";"></td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman"; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman";"></td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"></td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Laboratory equipment</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">4,631,962</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,801,545</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">336,524</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">305,214</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and fixtures</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">47,877</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">47,877</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">167,972</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">153,965</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 73%;;vertical-align:bottom;"></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">5,184,335</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">4,308,601</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(1,599,923</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(1,423,341</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 73%;;vertical-align:bottom;"></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Property and equipment, net</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,584,412</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2,885,260</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 73%;;vertical-align:bottom;"></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense was $174,331 and $141,178 for the three months ended March 31, 2021 and 2020, respectively. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

9196487

5098579

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following at March 31, 2021 and December 31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 73%;"></td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"></td><td style="font-family: "times new roman";"></td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman"; width: 3%;;vertical-align:bottom;"></td><td style="font-family: "times new roman";"></td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"></td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Laboratory equipment</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">4,631,962</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,801,545</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">336,524</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">305,214</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Furniture and fixtures</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">47,877</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">47,877</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">167,972</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">153,965</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 73%;;vertical-align:bottom;"></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">5,184,335</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">4,308,601</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(1,599,923</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(1,423,341</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 73%;;vertical-align:bottom;"></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 73%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Property and equipment, net</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,584,412</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2,885,260</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 73%;;vertical-align:bottom;"></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

200

1999

4631962

3801545

336524

305214

47877

167972

153965

5184335

4308601

1599923

1423341

292255

7887

174331

141178

464

550

1450

8974980

56500

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7. Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the components of accrued expenses is as follows as of March 31, 2021 and December 31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 72%;"> </td><td style="font-family: "times new roman"; width: 6%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 6%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/> <div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202<div style="display:inline;">1</div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">135,033</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">135,033</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries, benefits and related expenses</div></div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,567,071</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">1,924,405</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued severance</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">26,724</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,491</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">408,315</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other accrued expenses</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">137,403</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">108,550</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:top;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,842,998</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,603,027</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

115503948

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the components of accrued expenses is as follows as of March 31, 2021 and December 31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 72%;"> </td><td style="font-family: "times new roman"; width: 6%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 6%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div><br/> <div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">202<div style="display:inline;">1</div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div><br/> <div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">135,033</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">135,033</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries, benefits and related expenses</div></div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,567,071</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">1,924,405</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued severance</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">26,724</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,491</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">408,315</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 72%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other accrued expenses</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">137,403</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">108,550</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:top;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,842,998</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,603,027</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 72%;;vertical-align:bottom;"> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 6%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

20587

135033

2567071

1924405

26724

3491

408315

137403

108550

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11. Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During January 2017, the Company adopted the 2017 Equity Incentive Plan (the “2017 Plan”), which provides for granting of restricted stock, options to purchase shares of common stock and other awards to employees, directors and consultants. In March 2017, the Company amended the 2017 Plan to increase the number of available shares to <div style="letter-spacing: 0px; top: 0px;;display:inline;">660,838</div>. In June 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”) which provides for granting of restricted stock, options to purchase shares of common stock, and other awards to employees, directors and consultants, and reserved 1,741,770 shares for this purpose. The 2018 Plan was amended in July 2018 to increase the number of available shares to 1,809,143. In February 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 2,757,556 shares under the plan. No further shares will be issued under the 2017 and 2018 plans. There are 1,586,365 shares available for issuance under the 2021 plan. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The number of options to be granted under the 2021 Plan, the option exercise prices, and other terms of the options are determined by the Board of Directors in accordance with the terms of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plan. Generally</div></div><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, stock options are granted at fair value, become exercisable over a period of one to four years, expire in ten years or less and are subject to the employee’s continued employment</div>. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended March 31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 74%;"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;width:100%;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 74%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenses</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">204,330 </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">82,743</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 74%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">993,114 </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">236,219</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 74%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 74%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total stock-based compensation expense</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,197,444 </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">318,962</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 74%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of option activity under the Company’s Stock Option Plans: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; width: 92%;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width: 56%;"></td><td style="width: 4%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 3%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 4%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 4%;;vertical-align:bottom;"></td><td></td><td></td><td></td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Stock<br/> Options</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (years)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic Value<br/> (millions)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding as of January 1, 2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,233,185</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.52</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,170,891</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17.00</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(65,013</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.56</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancelled</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(772</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4.31</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(192,243</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.83</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 56%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March 31, 2021</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,146,048</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">8.44</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7.98</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">33.5</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 56%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested or expected to vest as of March 31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,146,048</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.44</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.98</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">33.5</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of March 31, 2021</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,730,292</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.18</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.64</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27.5</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Shares unvested as of March 31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,415,786</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14.86</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.63</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average fair value of the options granted during the three months ended March 31, 2021 and 2020 was $11.64 and $4.04, respectively. The options were valued using the Black-Scholes option-pricing model for the three months ended March 31, 2021 and 2020 with the following assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width: 66%;"></td><td style="width: 2%;;vertical-align:bottom;"></td><td></td><td style="width: 2%;;vertical-align:bottom;"></td><td></td></tr><tr><td style="padding-bottom: 1pt; width: 66%;;vertical-align:bottom;"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="text-align:center;;vertical-align:bottom;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="text-align:center;;vertical-align:bottom;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt; width: 66%;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">79.8<div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">%<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>to </div>81.0%</td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">100%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">0.6<div style="letter-spacing: 0px; top: 0px;;display:inline;">% to </div>0.7%</td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">0.7<div style="letter-spacing: 0px; top: 0px;;display:inline;">% to </div>0.74%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected dividend yield</div></div></td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">0%</td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">0%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div></td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">5.5<div style="letter-spacing: 0px; top: 0px;;display:inline;"> to </div>6.0 years</td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">5.3<div style="letter-spacing: 0px; top: 0px;;display:inline;"> to </div>6.0 years</td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total fair value of stock options vested during the three months ended March 31, 2021 and 2020 was approximately $0.8 million, and $0.4 million, respectively. The intrinsic value of stock options exercised for the three months ended March 31, 2021 and 2020 was approximately $232,268 and $0, respectively. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2021, there was $15.3 million of total unrecognized compensation expense related to unvested options that will be recognized over a weighted average period of 3.38 years. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.00

1741770

2757556

660838

1809143

1586365

11.64

4.04

15.3

P3Y4M17D

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended March 31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 74%;"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;width:100%;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 74%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development expenses</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">204,330 </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">82,743</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 74%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">993,114 </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">236,219</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 74%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 74%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total stock-based compensation expense</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,197,444 </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">318,962</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 74%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of option activity under the Company’s Stock Option Plans: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; width: 92%;;margin : 0px auto;;text-align:left;"><tr style="font-size: 0px;"><td style="width: 56%;"></td><td style="width: 4%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 3%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 4%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 4%;;vertical-align:bottom;"></td><td></td><td></td><td></td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Stock<br/> Options</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (years)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic Value<br/> (millions)</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding as of January 1, 2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,233,185</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3.52</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,170,891</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">17.00</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(65,013</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.56</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancelled</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(772</td><td style="white-space: nowrap;;vertical-align:bottom;">) </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">4.31</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td><td style="font-family: "times new roman";;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Forfeited</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(192,243</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4.83</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="font-family: "times new roman"; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 56%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March 31, 2021</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,146,048</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">8.44</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">7.98</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">33.5</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 56%;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Vested or expected to vest as of March 31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,146,048</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8.44</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7.98</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">33.5</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of March 31, 2021</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,730,292</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3.18</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">6.64</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">27.5</td><td style="white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 56%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Shares unvested as of March 31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,415,786</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 3%;;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">14.86</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.63</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">6.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

The options were valued using the Black-Scholes option-pricing model for the three months ended March 31, 2021 and 2020 with the following assumptions:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width: 66%;"></td><td style="width: 2%;;vertical-align:bottom;"></td><td></td><td style="width: 2%;;vertical-align:bottom;"></td><td></td></tr><tr><td style="padding-bottom: 1pt; width: 66%;;vertical-align:bottom;"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="text-align:center;;vertical-align:bottom;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="text-align:center;;vertical-align:bottom;"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt; width: 66%;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt; width: 2%;;vertical-align:bottom;">  </td><td style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">79.8<div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">%<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>to </div>81.0%</td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">100%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">0.6<div style="letter-spacing: 0px; top: 0px;;display:inline;">% to </div>0.7%</td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">0.7<div style="letter-spacing: 0px; top: 0px;;display:inline;">% to </div>0.74%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected dividend yield</div></div></td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">0%</td><td style="background-color: rgb(204, 238, 255); width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">0%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 66%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div></td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">5.5<div style="letter-spacing: 0px; top: 0px;;display:inline;"> to </div>6.0 years</td><td style="width: 2%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">5.3<div style="letter-spacing: 0px; top: 0px;;display:inline;"> to </div>6.0 years</td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

204330

82743

993114

236219

1197444

318962

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities outstanding at March 31, 2021 and 2020 have been excluded from the computation of diluted weighted average common shares outstanding, as the effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman";;width:95%;"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:1%;"></td><td style="font-family: "times new roman";"></td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"></td><td style="font-family: "times new roman";;vertical-align:bottom;;width:1%;"></td><td style="font-family: "times new roman";"></td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock options</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,146,048</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2,242,145</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">10,135,735</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Convertible debt</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants</div></div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">14,480</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,146,048</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">14,374,460</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

3146048

2242145

4733929

10135735

2059100

611

14480

9939688

14374460

2233185

1170891

65013

192243

3146048

1730292

1415786

3.52

17.00

4.56

4.83

8.44

3.18

14.86

P7Y11M23D

P6Y7M20D

P9Y7M17D

33500000

7441650

17.00

115191259

175137398

10144052

145000

31272224

3669010

250000000

0.0001

10000000

0.0001

6000000

145000

2896

0.01

145000

0.00

P5Y6M

P6Y

P5Y3M18D

P6Y

200000 325000 0

125000

P10Y 2.00

155000

26918

75000 1600000 400000 100000 4200000 100000 350000

15000000

9031480

0.06

25000

75000

P90D P150D P190D

2021-04-23

0.80 85000000

843619

0.90

843619

2022-04-23

0.0098

125000000 50000000

256212

613770

217593

40233

32749

0.798

0.810

0.006

0.007

0.0074

33500000

35047435

7685865

10887449

121735303

22047361

31209734

27500000

1450

145000 4.31 -772 -35048885 -7685865 -10887449 -121880303 -22047361 -31209734

35047435

7685865

10887449

121735303

22047361

31209734

126

8206938

-77582005

740058

-1537274

126

4705808

-47716008

506

-43009568

1256609

1254681

1014

53621185

53622199

10144052

367 30251689 30252056 3669010

744

114550571

114551315

7441650

297076

297083

65013

1197444

-8546551

-6315508

318962

2258

205847571

-85388498

126

5024770

-54031516

-49006620

22579219

1254681

0.03

P1Y

P4Y

P10Y

800000

400000

232268

1.00

1500000

722518

<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12. Net Loss Per Share Attributable to Common Stockholders </div> </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company’s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and warrants and the if-converted method is used to determine the dilutive effect of the Company’s redeemable convertible preferred stock and Convertible Notes. For the three months ended March 31, 2021 and 2020, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options and shares of redeemable convertible preferred stock were excluded from the calculation of diluted loss per share. Under the if converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive. The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2021 and 2020: </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 71%;"> </td><td style="font-family: "times new roman"; width: 5%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(8,332,414</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(6,315,508</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated dividends on Redeemable Convertible Preferred Stock</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(377,562</div></td><td style="white-space: nowrap;;vertical-align:bottom;">)<div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(815,516</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 71%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss attributable to common stockholders</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(8709,976</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(7,131,024</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 71%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(0.80</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(5.68</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average common shares outstanding</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">12,633,123</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,254,681</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities outstanding at March 31, 2021 and 2020 have been excluded from the computation of diluted weighted average common shares outstanding, as the effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 71%;"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock options</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,146,048</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2,242,145</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">10,135,735</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Convertible debt</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">—  </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants</div></div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">14,480</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">3,146,048</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">14,374,460</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2021 and 2020: </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="color: white; line-height: 0pt; visibility: hidden;"><td style="font-family: "times new roman"; width: 71%;"> </td><td style="font-family: "times new roman"; width: 5%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td><td style="font-family: "times new roman"; width: 4%;;vertical-align:bottom;"> </td><td style="font-family: "times new roman";"> </td><td style="white-space: nowrap;">                           </td><td style="font-family: "times new roman";"> </td></tr><tr><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman";"><div style="font-weight:bold;display:inline;width:100%;"> </div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div> </div></td></tr><tr style="font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2021</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;">  </td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2020</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(8,332,414</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(6,315,508</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated dividends on Redeemable Convertible Preferred Stock</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(377,562</div></td><td style="white-space: nowrap;;vertical-align:bottom;">)<div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(815,516</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 71%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss attributable to common stockholders</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(8709,976</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(7,131,024</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="font-family: "times new roman"; width: 71%;;vertical-align:bottom;"> </td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td><td> </td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per common share</div></div></td><td style="width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(0.80</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td><td style="width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">(5.68</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px;;display:inline;">) </div></td></tr><tr style="font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 71%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average common shares outstanding</div></div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">12,633,123</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="background-color: rgb(204, 238, 255); width: 4%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">1,254,681</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-family: "times new roman"; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"> </div></td></tr></table>

2011-06-07

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The recurring Level 3 fair value measurements of the embedded features of the Convertible Notes issued in January 2021 include the following significant unobservable inputs: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: "times new roman"; width: 85%;"></td><td style="font-family: "times new roman"; width: 11%;;vertical-align:bottom;"></td><td style="font-family: "times new roman"; width: 0%;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt; width: 85%;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: "times new roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable Input</div></div></div></td><td style="padding-bottom: 1pt; width: 11%;;vertical-align:bottom;">  </td><td style="border-bottom: 1pt solid rgb(0, 0, 0); width: 0%;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Assumptions</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Probabilities of conversion provisions</div></div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">5%-50%</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Estimated timing of conversion (years)</div></td><td style="width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.13-0.31</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Time period to maturity (years)</div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;">0.31</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of the Company’s stock</div></div></td><td style="width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$0.45-$0.56</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Stock price volatility</div></div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">76-90%</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-adjusted discount rate</div></div></td><td style="width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; width: 0%;;text-align:center;;vertical-align:bottom;">25.56%</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 85%;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Dividend yield</div></div></td><td style="background-color: rgb(204, 238, 255); width: 11%;;vertical-align:bottom;">  </td><td style="white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;;text-align:center;;vertical-align:bottom;">0%</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

-2277332

2896

-506

30252056

1982594

0.25

116636

2383986

xbrli:shares iso4217:USD xbrli:pure iso4217:USD xbrli:shares utr:Y

EX-101.SCH 8 nexi-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Statements Of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Statements Of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Statements Of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Cash and Cash Equivalents and Restricted Cash link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Convertible Notes link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Employee Benefit Plan link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Cash and Cash Equivalents and Restricted Cash (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Basis of Presentation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Cash and Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents And Restricted Cash (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements Categorized As Level 3 (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of the Convertible Notes (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Property and Equipment - Summary of Property And Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Accrued Expenses - Summary of Components of Accrued Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Convertible Notes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Basic and Diluted Earnings Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Employee Benefit Plan - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 nexi-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 nexi-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 nexi-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Information [Table] Document Information [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Document Quarterly Report Document Transition Report Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Security Exchange Name Trading Symbol Title of 12(b) Security Document Fiscal Year Focus Document Fiscal Period Focus Entity Interactive Data Current Entity Incorporation, State or Country Code Entity Address, State or Province Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Series A Redeemable Convertible Preferred Stock [Member] Series A Redeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock. Series A Two Redeemable Convertible Preferred Stock [Member] Series A-2 Redeemable Convertible Preferred Stock Series A Two Redeemable Convertible Preferred Stock. Series A Three Redeemable Convertible Preferred Stock [Member] Series A-3 Redeemable Convertible Preferred Stock Series A Three Redeemable Convertible Preferred Stock. Statement [Line Items] Statement [Line Items] Liabilities and Equity [Abstract] LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Derivative Liability, Current Derivative liability Other Liabilities, Current Other current liabilities Due to Related Parties, Current Convertible notes issued to related parties Convertible Notes Payable, Current Convertible notes Liabilities, Current Total current liabilities Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Commitments and Contingencies Commitments and contingencies Temporary Equity [Abstract] Redeemable convertible preferred stock Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount Total redeemable convertible preferred stock Temporary equity, Balance Temporary equity, Balance Other Liabilities, Noncurrent Other non-current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' deficit Common Stock, Value, Issued Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,579,219 issued and outstanding as of March 31, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional Paid in Capital Additional paid-in-capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' deficit Balance Balance Transition adjustment recorded in accumulated deficit Liabilities and Equity Total liabilities, redeemable convertible preferred stock and stockholders' deficit Assets [Abstract] ASSETS Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Other Assets, Noncurrent Other non-current assets Assets Total assets Assets, Current [Abstract] Current assets: Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Restricted Cash, Current Restricted cash Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Temporary Equity, Par or Stated Value Per Share Temporary equity, per share Temporary Equity, Shares Authorized Temporary equity, shares authorized Temporary Equity, Shares Issued Temporary equity, shares issued Temporary Equity, Shares Outstanding Temporary equity, shares outstanding Temporary equity, Balance, shares Temporary equity, Balance, shares Temporary Equity, Liquidation Preference Temporary equity, liquidation preference Income Statement [Abstract] Income Statement [Abstract] Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other (expense) income: Investment Income, Interest Interest income Interest Expense Interest expense Unrealized Gain (Loss) on Derivatives Change in fair value of derivative liabilities Other Nonoperating Income (Expense) Other income (expense) Nonoperating Income (Expense) Other income (expense) Revenues Revenue Operating Expenses [Abstract] Operating expenses: General and Administrative Expense General and administrative Operating Expenses Total operating expenses Research and Development Expense Research and development Net Income (Loss) Attributable to Parent Net loss Net loss Temporary Equity, Dividends, Adjustment Accumulated dividends on Redeemable Convertible Preferred Stock Net Income (Loss) Available to Common Stockholders, Basic Net loss available to common stockholders' Earnings Per Share, Basic and Diluted Basic and diluted net loss available to common stockholders per common share Basic and diluted net loss per common share Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted-average number of common shares outstanding Basic and diluted weighted average common shares outstanding Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized (loss) gain on available-for-sale marketable securities, net of tax Change in unrealized gains on marketable available-for-sale securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income/ (Loss) Temporary Equity, Stock Issued During Period, Value, New Issues Issuance of Series A redeemable preferred stock upon exercise of warrants Temporary Equity Stock Issued During Period Shares New Issues Issuance of Series A redeemable preferred stock upon exercise of warrants, shares Temporary Equity Stock Issued During Period Shares New Issues Temporary equity stock issued during period shares new issues. Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock into common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of preferred stock into common stock, Shares Stock Issued During Period Value Conversion Of Convertible Debt Conversion of convertible debt into common stock Stock issued during period value conversion of convertible debt. Stock Issued During Period Shares Conversion Of Convertible Debt Conversion of convertible debt into common stock, shares Stock issued during period shares conversion of convertible debt. Temporary Equity Stock Converted During Period Value Conversion of preferred stock into common stock, Temporary equity Temporary equity stock converted during period value. Temporary Equity Stock Converted During Period Shares Conversion of preferred stock into common stock, Temporary equity, shares Temporary equity stock converted during period shares. Shares, Outstanding Balance, Shares Balance, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options, Shares Stock options exercised APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Stock Issued During Period, Value, New Issues Issuance of common stock in connection with the initial public offering. net of transaction costs Stock Issued During Period, Shares, New Issues Issuance of common stock in connection with the initial public offering. net of transaction costs, Shares Stock issued during period shares Number Of Warrants Exercised Exercise of warrants, Shares Number of warrants exercised. Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative Effect, Period of Adoption, Adjustment [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Increase (Decrease) in Derivative Liabilities Change in fair value of derivative liability Gain (Loss) on Disposition of Assets Gain (loss) on asset disposal Share-based Payment Arrangement, Noncash Expense Stock-based compensation Paid-in-Kind Interest Non-cash interest expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accrued Liabilities Accrued expenses, deferred rent and other Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Repayments of Long-term Capital Lease Obligations Principal payments on capital leases Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Proceeds from Warrant Exercises Proceeds from the exercise of warrants Proceeds from Convertible Debt Proceeds from the issuance of convertible notes Proceeds from Related Party Debt Proceeds from the issuance of convertible notes from related parties Proceeds from Issuance Initial Public Offering Proceeds from initial public offering, net of transaction costs Proceeds From Issuance Of IPO Payments of Debt Issuance Costs Issuance costs associated with convertible notes Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net cash, cash equivalents and restricted cash at beginning of period Net cash, cash equivalents and restricted cash at end of period Total Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid during the year for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of noncash investing and financing activities: Capital Expenditures Incurred but Not yet Paid Property and equipment purchases included in accounts payable and accrued expenses Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Proceeds from maturities and sales of available-for-sale marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Proceeds from Sale of Machinery and Equipment Proceeds from disposal of equipment Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Fund Long-term Loans to Related Parties Employee advances Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Description and Basis of Presentation [Text Block] Nature of the Business and Basis of Presentation Accounting Policies [Abstract] Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Basis of presentation Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Disclosure [Text Block] Cash and Cash Equivalents and Restricted cash Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair value measurements Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid Expenses And Other Current Assets [Text Block] Prepaid expenses and other current assets Prepaid expenses and other current assets. Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property and equipment Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued expenses Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Convertible notes Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract] Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract] Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Abstract]. Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Text Block] Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Text Block]. Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Text Block] Stock-based compensation Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Net Loss Per Share Attributable to Common Stockholders Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Retirement Benefits [Abstract] Retirement Benefits [Abstract] Retirement Benefits [Text Block] Employee Benefit Plan Basis of Accounting, Policy [Policy Text Block] Basis of Presentation New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting standards and pronouncements Cash, Cash Equivalents and Investments [Table Text Block] Summary of reconciliation of cash, cash equivalents, and restricted cash Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of fair value measurements categorized as Level 3 Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Summary of fair value measurements of the convertible notes Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Summary of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Summary of property and equipment Schedule of Accrued Liabilities [Table Text Block] Summary of the components of accrued expenses Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of stock-based compensation expense EX-101.PRE 12 nexi-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Cover Page	3 Months Ended
Cover Page	Mar. 31, 2021 shares
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Registrant Name	NexImmune, Inc.
Entity Central Index Key	0001538210
Entity Address, State or Province	MD
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock
Trading Symbol	NEXI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding	22,579,219

XML 14 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 118,102,945	$ 5,031,079
Restricted cash	67,500	67,500
Prepaid expenses and other current assets	4,788,019	3,293,858
Total current assets	122,958,464	8,392,437
Property and equipment, net	3,584,412	2,885,260
Other non-current assets	23,373	23,373
Total assets	126,566,249	11,301,070
Current liabilities:
Accounts payable	2,406,537	2,760,129
Accrued expenses	2,842,998	2,603,027
Derivative liability		1,702,359
Other current liabilities	843,619	843,619
Convertible notes issued to related parties		7,324,267
Convertible notes		11,793,397
Total current liabilities	6,093,154	27,026,798
Deferred rent, net of current portion	11,764	23,529
Other non-current liabilities		4,935
Total liabilities	6,104,918	27,055,262
Commitments and contingencies
Redeemable convertible preferred stock
Total redeemable convertible preferred stock		53,620,749
Stockholders' deficit
Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,579,219 issued and outstanding as of March 31, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020.	2,258	126
Additional paid-in-capital	205,847,571	8,206,938
Accumulated deficit	(85,388,498)	(77,582,005)
Total stockholders' deficit	120,461,331	(69,374,941)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	$ 126,566,249	11,301,070
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock
Total redeemable convertible preferred stock		35,047,435
Series A-2 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock
Total redeemable convertible preferred stock		7,685,865
Series A-3 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock
Total redeemable convertible preferred stock		$ 10,887,449

XML 15 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	22,579,219	1,256,609
Common stock, shares outstanding	22,579,219	1,256,609
Series A Redeemable Convertible Preferred Stock
Temporary equity, per share	$ 0.0001	$ 0.0001
Temporary equity, shares authorized		121,735,303
Temporary equity, shares issued		121,735,303
Temporary equity, shares outstanding	0	121,735,303
Temporary equity, liquidation preference		$ 42,314,789
Series A-2 Redeemable Convertible Preferred Stock
Temporary equity, per share	$ 0.0001	$ 0.0001
Temporary equity, shares authorized		28,384,899
Temporary equity, shares issued		22,047,361
Temporary equity, shares outstanding	0	22,047,361
Temporary equity, liquidation preference		$ 8,683,746
Series A-3 Redeemable Convertible Preferred Stock
Temporary equity, per share	$ 0.0001	$ 0.0001
Temporary equity, shares authorized		34,061,879
Temporary equity, shares issued		31,209,734
Temporary equity, shares outstanding	0	31,209,734
Temporary equity, liquidation preference		$ 11,699,176

XML 16 R4.htm IDEA: XBRL DOCUMENT

Statements Of Operations - USD ($)	3 Months Ended
Statements Of Operations - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue	$ 0
Operating expenses:
Research and development	6,012,608	$ 4,272,167
General and administrative	4,057,592	2,088,401
Total operating expenses	10,070,200	6,360,568
Loss from operations	(10,070,200)	(6,360,568)
Other (expense) income:
Interest income	3,613	18,684
Interest expense	(904,119)	(989)
Change in fair value of derivative liabilities	2,424,877
Other income (expense)	(722)	27,365
Other income (expense)	1,523,649	45,060
Net loss	(8,546,551)	(6,315,508)
Accumulated dividends on Redeemable Convertible Preferred Stock	(377,562)	(815,516)
Net loss available to common stockholders'	$ (8,924,113)	$ (7,131,024)
Basic and diluted net loss available to common stockholders per common share	$ (0.71)	$ (5.68)
Basic and diluted weighted-average number of common shares outstanding	12,633,123	1,254,681

XML 17 R5.htm IDEA: XBRL DOCUMENT

Statements Of Comprehensive Loss - USD ($)	3 Months Ended
Statements Of Comprehensive Loss - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (8,546,551)	$ (6,315,508)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale marketable securities, net of tax		(506)
Comprehensive loss	$ (8,546,551)	$ (6,316,014)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 18 R6.htm IDEA: XBRL DOCUMENT

Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Deficit - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Other Comprehensive Income/ (Loss)	Series A Redeemable Convertible Preferred Stock	Series A-2 Redeemable Convertible Preferred Stock	Series A-3 Redeemable Convertible Preferred Stock
Temporary equity, Balance at Dec. 31, 2019									$ 35,047,435	$ 7,685,865	$ 10,887,449
Temporary equity, Balance, shares at Dec. 31, 2019									121,735,303	22,047,361	31,209,734
Balance at Dec. 31, 2019	$ (43,009,568)		$ 126	$ 4,705,808		$ (47,716,008)		$ 506
Balance, Shares at Dec. 31, 2019			1,254,681
Net loss	(6,315,508)					(6,315,508)
Stock-based compensation	318,962			318,962
Change in unrealized gains on marketable available-for-sale securities	(506)							$ (506)
Balance at Mar. 31, 2020	(49,006,620)		$ 126	5,024,770		(54,031,516)
Balance, Shares at Mar. 31, 2020			1,254,681
Temporary equity, Balance at Mar. 31, 2020									$ 35,047,435	$ 7,685,865	$ 10,887,449
Temporary equity, Balance, shares at Mar. 31, 2020									121,735,303	22,047,361	31,209,734
Temporary equity, Balance at Dec. 31, 2020	53,620,749								$ 35,047,435	$ 7,685,865	$ 10,887,449
Temporary equity, Balance, shares at Dec. 31, 2020									121,735,303	22,047,361	31,209,734
Balance at Dec. 31, 2020	(69,374,941)	$ (1,537,274)	$ 126	8,206,938	$ (2,277,332)	(77,582,005)	$ 740,058
Balance, Shares at Dec. 31, 2020			1,256,609
Issuance of Series A redeemable preferred stock upon exercise of warrants									$ 1,450
Issuance of Series A redeemable preferred stock upon exercise of warrants, shares									145,000
Conversion of preferred stock into common stock, Temporary equity									$ (35,048,885)	$ (7,685,865)	$ (10,887,449)
Conversion of preferred stock into common stock, Temporary equity, shares									(121,880,303)	(22,047,361)	(31,209,734)
Conversion of preferred stock into common stock	53,622,199		$ 1,014	53,621,185
Conversion of preferred stock into common stock, Shares			10,144,052
Conversion of convertible debt into common stock	30,252,056		$ 367	30,251,689
Conversion of convertible debt into common stock, shares			3,669,010
Issuance of common stock in connection with the initial public offering. net of transaction costs	114,551,315		$ 744	114,550,571
Issuance of common stock in connection with the initial public offering. net of transaction costs, Shares			7,441,650
Exercise of stock options	$ 297,083		$ 7	297,076
Exercise of stock options, Shares	65,013		65,013
Exercise of warrants, Shares			2,896
Net loss	$ (8,546,551)					(8,546,551)
Stock-based compensation	1,197,444			1,197,444
Balance at Mar. 31, 2021	$ 120,461,331		$ 2,258	$ 205,847,571		$ (85,388,498)
Balance, Shares at Mar. 31, 2021			22,579,219
Temporary equity, Balance, shares at Mar. 31, 2021									0	0	0

XML 19 R7.htm IDEA: XBRL DOCUMENT

Statements Of Cash Flows - USD ($)	3 Months Ended
Statements Of Cash Flows - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (8,546,551)	$ (6,315,508)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	174,331	143,518
Gain (loss) on asset disposal	(464)	398
Stock-based compensation	1,197,444	318,962
Non-cash interest expense	903,919
Change in fair value of derivative liability	(2,424,877)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(2,446,793)	(929,007)
Accounts payable	(645,847)	(191,877)
Accrued expenses, deferred rent and other	633,307	463,090
Net cash used in operating activities	(11,155,532)	(6,510,424)
Cash flows from investing activities
Purchase of property and equipment	(581,228)	(241,519)
Proceeds from disposal of equipment	464	550
Employee advances		(494)
Proceeds from maturities and sales of available-for-sale marketable securities		999,780
Net cash provided by (used in) investing activities	(580,764)	758,317
Cash flows from financing activities
Proceeds from initial public offering, net of transaction costs	115,503,948
Proceeds from the exercise of stock options	297,083
Proceeds from the exercise of warrants	1,450
Principal payments on capital leases	(5,212)	(4,832)
Proceeds from the issuance of convertible notes from related parties	56,500
Proceeds from the issuance of convertible notes	8,974,980
Issuance costs associated with convertible notes	(20,587)
Net cash provided by (used in) financing activities	124,808,162	(4,832)
Net increase (decrease) in cash, cash equivalents and restricted cash	113,071,866	(4,097,908)
Net cash, cash equivalents and restricted cash at beginning of period	5,098,579	9,196,487
Net cash, cash equivalents and restricted cash at end of period	118,170,445	5,098,579
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	200	1,999
Supplemental disclosure of noncash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$ 292,255	$ 7,887

XML 20 R8.htm IDEA: XBRL DOCUMENT

Nature of the Business and Basis of Presentation

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of the Business and Basis of Presentation

1. Nature of the business and basis of presentation

co-stimulatory

signals to specific T cells, generating an immune response that can be directed toward any foreign substance or cell type in a patient’s body. The Company’s first two products, both for the treatment of different types of cancer, entered clinical trials in 2020.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of presentation

2. Basis of Presentation

Basis of Presentation

Form 10-K

for the year ended December 31, 2020, as filed with the SEC on March 31, 2021.

Recent accounting standards and pronouncements

Recently Adopted

In August 2020, the FASB issued ASU

2020-06,

an update to ASC Topic 470, Subtopic - 20,

Debt - Debt with Conversion and Other Options, and ASC Topic 815, Subtopic – 4,

Derivatives and Hedging - Contracts in Entity’s Own Equity

. ASU

2020-06

simplifies the guidance for certain financial instruments with characteristics of liability and equity, including convertible instruments and contracts on an entity’s own equity by reducing the number of accounting models for convertible instruments and amends guidance in ASC Topic 260, Earnings Per Share, relating to the computation of earnings per share for convertible instruments and contracts on an entity’s own equity. ASU

2020-06

is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2021, with early adoption permitted for fiscal years that begin after December 15, 2020. The Company early adopted this standard effective January 1, 2021 using the modified retrospective method. Under this standard, only conversion features embedded in the debt instrument that are accounted for as derivatives in accordance with ASC 815 or under the substantial premium model in ASC 470, require separate accounting. Prior to the adoption of this standard, the Company had recorded a beneficial conversion feature as a discount to convertible notes issued. Upon adoption of this standard, the beneficial conversion feature is no longer separately bifurcated. As a result of applying the modified retrospective method, the Company recognized a transition adjustment

$0.7

million recorded in accumulated deficit, a reduction of additional paid-in capital of $2.2 million and an increase to the carrying value of the convertible notes of $1.5 million on January 1, 2021.

Not Yet Adopted

In February 2016, the FASB issued ASU

No. 2016-02,

Leases (Topic 842)

. The guidance requires lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding leasing arrangements. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting the new lease standards, and a package of practical expedients an entity can elect to utilize to reduce the level of effort required for adoption. Under the transition option, entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements. In November 2019, the FASB issued ASU

2019-10

deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU

2020-05

which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The Company is currently reviewing its leases and other contracts to determine the impact the adoption of this guidance will have on the financial statements. The Company currently expects that the adoption of this guidance will change the way it accounts for its operating leases, and will result in recording

right-of-use

assets and lease liabilities in the balance sheets, and result in additional lease-related disclosures in the footnotes to the financial statements. The Company expects that it will adopt this guidance utilizing the modified retrospective approach and elect the package of practical expedients.

In June 2016, the FASB issued ASU

2016-13,

Financial Instruments – Credit Losses (Topic 326)

, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for

available-for-sale

debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December 15, 2022, and interim periods beginning after December 15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company’s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU

2016-13

is not expected to have a material impact on its financial position, results of operations or the related disclosures.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents and Restricted Cash

3 Months Ended

Mar. 31, 2021

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents and Restricted cash

3. Cash and Cash Equivalents and Restricted cash


	March 31, 2021		December 31, 2020
Cash and cash equivalents	$	118,102,945	$	5,031,079
Restricted cash		67,500		67,500

Total	$	118,170,445	$	5,098,579

Amounts included in restricted cash represent those required as collateral on corporate credit cards.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Fair value measurements

4. Fair Value Measurements

Level 1 -

Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2 -

Level 3 -

Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.


Balance as of December 31, 2020	$	1,702,359
Fair value of derivative liabilities issued		722,518
Reduction in expense related to fair value changes in derivative liabilities		(2,424,877	)

Balance as of March 31, 2021	$	—

The fair value of the derivative liability was determined using a binomial lattice model by calculating and comparing the fair value of the Convertible Notes with and without the embedded features.

The recurring Level 3 fair value measurements of the embedded features of the Convertible Notes issued in January 2021 include the following significant unobservable inputs:


Unobservable Input		Assumptions
Probabilities of conversion provisions		5%-50%
Estimated timing of conversion (years)		0.13-0.31
Time period to maturity (years)		0.31
Fair value of the Company’s stock		$0.45-$0.56
Stock price volatility		76-90%
Risk-adjusted discount rate		25.56%
Dividend yield		0%

zero.

All derivative instruments were eliminated following the conversion of the Convertible Notes on February 11, 2021.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2021

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid expenses and other current assets

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following at March 31, 2021 and December 31, 2020:



	March 31, 2021		December 31, 2020
Prepaid research and development expenses	$	1,922,643	$	1,894,785
Prepaid maintenance agreements		113,059		144,575
Prepaid insurance		2,608,493		98,421
Prepaid other		143,824		124,929
Deferred financing costs		—		952,633
Other current assets		—		78,515

	$	4,788,019	$	3,293,858

XML 25 R13.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and equipment

6. Property and Equipment

Property and equipment consist of the following at March 31, 2021 and December 31, 2020:



	March 31, 2021			December 31, 2020
Laboratory equipment	$	4,631,962		$	3,801,545
Computer equipment and software		336,524			305,214
Furniture and fixtures		47,877			47,877
Leasehold improvements		167,972			153,965

		5,184,335			4,308,601
Less accumulated depreciation and amortization		(1,599,923	)		(1,423,341	)

Property and equipment, net	$	3,584,412		$	2,885,260

Depreciation and amortization expense was $174,331 and $141,178 for the three months ended March 31, 2021 and 2020, respectively.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2021

Payables and Accruals [Abstract]

Accrued expenses

7. Accrued Expenses

A summary of the components of accrued expenses is as follows as of March 31, 2021 and December 31, 2020:



	March 31, 202 1		December 31, 2020
Accrued professional fees	$	135,033	$	135,033
Accrued salaries, benefits and related expenses		2,567,071		1,924,405
Accrued severance		—		26,724
Accrued interest		3,491		408,315
Other accrued expenses		137,403		108,550

	$	2,842,998	$	2,603,027

XML 27 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

8. Commitments and Contingencies

Maryland Biotechnology Center Grant

Johns Hopkins University Exclusive License Agreement

non-clinical

field. In the aggregate, the Company may be required to pay JHU additional milestone fees of up to $4.2 million for all clinical, regulatory and commercial milestones for all licensed products or licensed services in the therapeutic field, the diagnostic field and the

non-clinical

field. The Company may also be required to pay royalties in the low to upper

mid-single

digits on net sales of therapeutic products, diagnostic products and

non-clinical

products. The Company is required to make minimum annual royalty payments of $100,000 to

JHU under the A&R JHU License Agreement through the term of the agreement. The Company may also be required to pay JHU a low double digit percentage of any

non-royalty

sublicense consideration we receive.

The Company will record a liability when such events become probable. The Company has not reached any of the milestones or transacted its first commercial sale as of March 31, 2021.

Paycheck Protection Program Loan

24-week

period, at the Company’s option.

24-week

period following receipt of the loan proceeds. The Company submitted the PPP Loan forgiveness application in March 2021. The Company cannot provide any objective assurance that it will obtain forgiveness in whole or in part.

Contingencies

not

involved in any material legal proceedings.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Convertible Notes

3 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Convertible notes

9. Convertible Notes

The Convertible Notes had a scheduled maturity date of

April 23, 2021.

non-qualified

financing events (“Optional Conversion 1”). Upon Mandatory Conversion and Optional Conversion 1, the outstanding principal amount and all accrued and unpaid interest would automatically convert into the Company’s preferred stock of the same series issued in such equity financing and would be equal to the number of preferred stock obtained by dividing (a) all principal and accrued but unpaid interest under such Convertible Note by (b) the price per share paid by the other purchasers of the preferred stock sold in such equity financing multiplied by

80%.

If the Mandatory Conversion and Optional Conversion 1 did not

occur

by the maturity date, the outstanding principal amount plus all accrued and unpaid interest would be converted at the option of the holder into Company’s common stock at the price per share obtained by dividing

$85 million by the Company’s fully-diluted capitalization (“Optional Conversion 2”).

90% of the price per share paid by the purchasers of such stock in such a transaction and (b) the price per share obtained by dividing $125 million by the Company’s fully-diluted capitalization (“Change in Control”).

$9,031,480.

The Company amortized the debt issuance costs of $256,212

and the debt discount from of the initial value of the derivative liability of

$1,982,594 over the term of the Convertible Notes using the effective interest method. The debt issuance costs and debt discount amortization expense for the three months ended March 31, 2021 was $613,770 and is included in interest expense in the accompanying statements of operations. The interest expense at 6% of the Convertible Notes’ principal amount for the three months ended March 31, 2021 was $217,593

The effective interest rate during the three months ended March 31, 2021 was 25%. The unamortized debt issuance costs and debt discount on the Convertible Notes as of December 31, 2020, were $116,636 and $2,383,986, respectively.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit

3 Months Ended

Mar. 31, 2021

Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract]

Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit

10. Series A Redeemable Convertible Preferred Stock and Stockholders’ Deficit

Issuances of Common Stock

Convertible Notes principal

and accrued but unpaid interest thereon of $31,272,224 converted to 3,669,010 shares of common stock . Upon completion of the offering on February 11, 2021, the Company’s authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock-based compensation

11. Stock-Based Compensation

660,838

. In June 2018, the Company adopted the 2018 Equity Incentive Plan (the “2018 Plan”) which provides for granting of restricted stock, options to purchase shares of common stock, and other awards to employees, directors and consultants, and reserved 1,741,770 shares for this purpose. The 2018 Plan was amended in July 2018 to increase the number of available shares to 1,809,143. In February 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 2,757,556 shares under the plan. No further shares will be issued under the 2017 and 2018 plans. There are 1,586,365 shares available for issuance under the 2021 plan.

The number of options to be granted under the 2021 Plan, the option exercise prices, and other terms of the options are determined by the Board of Directors in accordance with the terms of the

202

Plan. Generally

, stock options are granted at fair value, become exercisable over a period of one to four years, expire in ten years or less and are subject to the employee’s continued employment

Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended March 31, 2021 and 2020:



	2021		2020
Research and development expenses	$	204,330	$	82,743
General and administrative expenses		993,114		236,219

Total stock-based compensation expense	$	1,197,444	$	318,962

The following is a summary of option activity under the Company’s Stock Option Plans:



	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (millions)
Outstanding as of January 1, 2021		2,233,185		$	3.52
Granted		1,170,891			17.00
Exercised		(65,013	)		4.56
Cancelled		(772	)		4.31
Forfeited		(192,243	)		4.83

Outstanding as of March 31, 2021		3,146,048		$	8.44		7.98	$	33.5

Vested or expected to vest as of March 31, 2021		3,146,048		$	8.44		7.98	$	33.5
Exercisable as of March 31, 2021		1,730,292		$	3.18		6.64	$	27.5
Shares unvested as of March 31, 2021		1,415,786		$	14.86		9.63	$	6.0



	2021	2020
Expected volatility	79.8 % to 81.0%	100%
Risk-free interest rate	0.6 % to 0.7%	0.7 % to 0.74%
Expected dividend yield	0%	0%
Expected term	5.5 to 6.0 years	5.3 to 6.0 years

As of March 31, 2021, there was $15.3 million of total unrecognized compensation expense related to unvested options that will be recognized over a weighted average period of 3.38 years.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders

12. Net Loss Per Share Attributable to Common Stockholders



	March 31, 2021			March 31, 2020
Net loss	$	(8,332,414	)	$	(6,315,508	)
Accumulated dividends on Redeemable Convertible Preferred Stock		(377,562	)		(815,516	)

Net loss attributable to common stockholders	$	(8709,976	)	$	(7,131,024	)

Basic and diluted net loss per common share	$	(0.80	)	$	(5.68	)
Basic and diluted weighted average common shares outstanding		12,633,123			1,254,681



	March 31, 2021		March 31, 2020
Stock options		3,146,048		2,242,145
Redeemable convertible preferred stock		—		10,135,735
Convertible debt		—		—
Warrants		—		14,480
Total		3,146,048		14,374,460

two-class

method.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

13. Income Taxes

more-likely-than-not

to be realized at March 31, 2021 and December 31, 2021. The effective tax rate for the three months ended March 31, 2021 and 2020 is 0%.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 33 R21.htm IDEA: XBRL DOCUMENT

Employee Benefit Plan

3 Months Ended

Mar. 31, 2021

Retirement Benefits [Abstract]

Employee Benefit Plan

14. Employee Benefit Plan

pre-tax

basis. The Company may contribute a matching contribution at its discretion. During the three months ended March 31, 2021 and 2020, the Company made contributions of $40,233 and $32,749, respectively, to the plan.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

+ Details

XML 34 R22.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Form 10-K

for the year ended December 31, 2020, as filed with the SEC on March 31, 2021.

Recent accounting standards and pronouncements

Recently Adopted

In August 2020, the FASB issued ASU

2020-06,

an update to ASC Topic 470, Subtopic - 20,

Debt - Debt with Conversion and Other Options, and ASC Topic 815, Subtopic – 4,

Derivatives and Hedging - Contracts in Entity’s Own Equity

. ASU

2020-06

$0.7

million recorded in accumulated deficit, a reduction of additional paid-in capital of $2.2 million and an increase to the carrying value of the convertible notes of $1.5 million on January 1, 2021.

Not Yet Adopted

In February 2016, the FASB issued ASU

No. 2016-02,

Leases (Topic 842)

2019-10

2020-05

right-of-use

In June 2016, the FASB issued ASU

2016-13,

Financial Instruments – Credit Losses (Topic 326)

, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for

available-for-sale

2016-13

is not expected to have a material impact on its financial position, results of operations or the related disclosures.

XML 35 R23.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents and Restricted Cash (Tables)

3 Months Ended

Mar. 31, 2021

Cash and Cash Equivalents [Abstract]

Summary of reconciliation of cash, cash equivalents, and restricted cash


	March 31, 2021		December 31, 2020
Cash and cash equivalents	$	118,102,945	$	5,031,079
Restricted cash		67,500		67,500

Total	$	118,170,445	$	5,098,579

XML 36 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Summary of fair value measurements categorized as Level 3

The following table presents activity related to the Company’s fair value measurements categorized as Level 3 of the valuation hierarchy, valued on a recurring basis:


Balance as of December 31, 2020	$	1,702,359
Fair value of derivative liabilities issued		722,518
Reduction in expense related to fair value changes in derivative liabilities		(2,424,877	)

Balance as of March 31, 2021	$	—

Summary of fair value measurements of the convertible notes

The recurring Level 3 fair value measurements of the embedded features of the Convertible Notes issued in January 2021 include the following significant unobservable inputs:


Unobservable Input		Assumptions
Probabilities of conversion provisions		5%-50%
Estimated timing of conversion (years)		0.13-0.31
Time period to maturity (years)		0.31
Fair value of the Company’s stock		$0.45-$0.56
Stock price volatility		76-90%
Risk-adjusted discount rate		25.56%
Dividend yield		0%

XML 37 R25.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2021

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Summary of prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following at March 31, 2021 and December 31, 2020:



	March 31, 2021		December 31, 2020
Prepaid research and development expenses	$	1,922,643	$	1,894,785
Prepaid maintenance agreements		113,059		144,575
Prepaid insurance		2,608,493		98,421
Prepaid other		143,824		124,929
Deferred financing costs		—		952,633
Other current assets		—		78,515

	$	4,788,019	$	3,293,858

XML 38 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Summary of property and equipment

Property and equipment consist of the following at March 31, 2021 and December 31, 2020:



	March 31, 2021			December 31, 2020
Laboratory equipment	$	4,631,962		$	3,801,545
Computer equipment and software		336,524			305,214
Furniture and fixtures		47,877			47,877
Leasehold improvements		167,972			153,965

		5,184,335			4,308,601
Less accumulated depreciation and amortization		(1,599,923	)		(1,423,341	)

Property and equipment, net	$	3,584,412		$	2,885,260

XML 39 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2021

Payables and Accruals [Abstract]

Summary of the components of accrued expenses

A summary of the components of accrued expenses is as follows as of March 31, 2021 and December 31, 2020:



	March 31, 202 1		December 31, 2020
Accrued professional fees	$	135,033	$	135,033
Accrued salaries, benefits and related expenses		2,567,071		1,924,405
Accrued severance		—		26,724
Accrued interest		3,491		408,315
Other accrued expenses		137,403		108,550

	$	2,842,998	$	2,603,027

XML 40 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Summary of stock-based compensation expense

Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended March 31, 2021 and 2020:



	2021		2020
Research and development expenses	$	204,330	$	82,743
General and administrative expenses		993,114		236,219

Total stock-based compensation expense	$	1,197,444	$	318,962

Summary of option activity

The following is a summary of option activity under the Company’s Stock Option Plans:



	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (millions)
Outstanding as of January 1, 2021		2,233,185		$	3.52
Granted		1,170,891			17.00
Exercised		(65,013	)		4.56
Cancelled		(772	)		4.31
Forfeited		(192,243	)		4.83

Outstanding as of March 31, 2021		3,146,048		$	8.44		7.98	$	33.5

Vested or expected to vest as of March 31, 2021		3,146,048		$	8.44		7.98	$	33.5
Exercisable as of March 31, 2021		1,730,292		$	3.18		6.64	$	27.5
Shares unvested as of March 31, 2021		1,415,786		$	14.86		9.63	$	6.0

Summary of black-scholes option pricing model

The options were valued using the Black-Scholes option-pricing model for the three months ended March 31, 2021 and 2020 with the following assumptions:



	2021	2020
Expected volatility	79.8 % to 81.0%	100%
Risk-free interest rate	0.6 % to 0.7%	0.7 % to 0.74%
Expected dividend yield	0%	0%
Expected term	5.5 to 6.0 years	5.3 to 6.0 years

XML 41 R29.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Summary of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2021 and 2020:



	March 31, 2021			March 31, 2020
Net loss	$	(8,332,414	)	$	(6,315,508	)
Accumulated dividends on Redeemable Convertible Preferred Stock		(377,562	)		(815,516	)

Net loss attributable to common stockholders	$	(8709,976	)	$	(7,131,024	)

Basic and diluted net loss per common share	$	(0.80	)	$	(5.68	)
Basic and diluted weighted average common shares outstanding		12,633,123			1,254,681

Summary of antidilutive securities outstanding


	March 31, 2021		March 31, 2020
Stock options		3,146,048		2,242,145
Redeemable convertible preferred stock		—		10,135,735
Convertible debt		—		—
Warrants		—		14,480
Total		3,146,048		14,374,460

XML 42 R30.htm IDEA: XBRL DOCUMENT

Nature of the Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity Incorporation date	Jun. 07, 2011

XML 43 R31.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Detail) - USD ($)	Mar. 31, 2021	Jan. 01, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transition adjustment recorded in accumulated deficit	$ 120,461,331		$ (69,374,941)	$ (49,006,620)	$ (43,009,568)
Convertible notes			11,793,397
Cumulative Effect, Period of Adoption, Adjustment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transition adjustment recorded in accumulated deficit			(1,537,274)
Convertible notes		$ 1,500,000
Retained Earnings [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transition adjustment recorded in accumulated deficit	(85,388,498)		(77,582,005)	(54,031,516)	(47,716,008)
Retained Earnings [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transition adjustment recorded in accumulated deficit		700,000	740,058
Additional Paid-in Capital [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transition adjustment recorded in accumulated deficit	$ 205,847,571		8,206,938	$ 5,024,770	$ 4,705,808
Additional Paid-in Capital [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transition adjustment recorded in accumulated deficit		$ 2,200,000	$ (2,277,332)

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 44 R32.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents And Restricted Cash (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 118,102,945	$ 5,031,079
Restricted cash	67,500	67,500
Total	$ 118,170,445	$ 5,098,579	$ 5,098,579	$ 9,196,487

XML 45 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Fair Value Measurements Categorized As Level 3 (Detail) - Embedded Derivative Financial Instruments - Fair Value, Recurring	3 Months Ended
	Mar. 31, 2021 USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,702,359
Fair value of derivative liabilities issued	722,518
Reduction in expense related to fair value changes in derivative liabilities	(2,424,877)
Ending balance	$ 0

XML 46 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Fair Value Measurements of the Convertible Notes (Detail) - Embedded Derivative Financial Instruments - Level 3	Jan. 01, 2021 yr
Probabilities of conversion provisions \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	5,000
Probabilities of conversion provisions \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	500
Estimated timing of conversion \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	0.31
Estimated timing of conversion \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	0.13
Time period to maturity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	0.31
Fair value of the Company's stock \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	0.56
Fair value of the Company's stock \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	0.45
Stock price volatility \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	9,000
Stock price volatility \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	7,600
Risk-adjusted discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	2,556
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Input	0

XML 47 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail)	Mar. 31, 2021 USD ($)
Fair Value Disclosures [Abstract]
Derivative liability	$ 0

XML 48 R36.htm IDEA: XBRL DOCUMENT

Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development expenses	$ 1,922,643	$ 1,894,785
Prepaid maintenance agreements	113,059	144,575
Prepaid insurance	2,608,493	98,421
Prepaid other	143,824	124,929
Deferred financing costs		952,633
Other current assets		78,515
Prepaid expenses and other current assets	$ 4,788,019	$ 3,293,858

XML 49 R37.htm IDEA: XBRL DOCUMENT

Property and Equipment - Summary of Property And Equipment (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 5,184,335	$ 4,308,601
Less accumulated depreciation and amortization	(1,599,923)	(1,423,341)
Property and equipment, net	3,584,412	2,885,260
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	4,631,962	3,801,545
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	336,524	305,214
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	47,877	47,877
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 167,972	$ 153,965

XML 50 R38.htm IDEA: XBRL DOCUMENT

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 174,331	$ 141,178

XML 51 R39.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Summary of Components of Accrued Expenses (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued professional fees	$ 135,033	$ 135,033
Accrued salaries, benefits and related expenses	2,567,071	1,924,405
Accrued severance		26,724
Accrued interest	3,491	408,315
Other accrued expenses	137,403	108,550
Accrued expenses	$ 2,842,998	$ 2,603,027

XML 52 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)			3 Months Ended
	Jan. 01, 2017	May 23, 2013	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Apr. 23, 2020	May 23, 2012
Research and development arrangement contract to perform for others compensation earned		$ 125,000
Accrued royalties			$ 75,000	$ 75,000
Loss contingency accrual			$ 0		$ 0
Other Current Liabilities [Member]
Notes payable, current						$ 843,619
Paycheck Protection Program Loan [Member]
Debt instrument, face amount						$ 843,619
Debt instrument, maturity date			Apr. 23, 2022
Debt instrument, interest rate			0.98%
Research and development expenses [Member] \| Minimum [Member]
Royalty expense			$ 25,000	$ 25,000
Maryland Biotechnology Center [Member] \| Translational Research Award Agreement [Member]
Research and development arrangement contract to perform for others liability		$ 325,000	0				$ 200,000
Research and development arrangement annual payment percentage		3.00%
Research and development arrangement contractual payment period		10 years
Research and development arrangement contractual payment percentage		200.00%
Revenue from contract with customer, including assessed tax			0
Johns Hopkins University [Member] \| Exclusive License Agreement [Member]
Upfront payment	$ 155,000
Stock issued during period, shares, issued for services	26,918
Milestone fees	$ 4,200,000
Minimum annual royalty payments			100,000
Cumulative minimum royalties			$ 350,000
Johns Hopkins University [Member] \| Exclusive License Agreement [Member] \| Clinical Trial Milestones [Member]
Milestone fees	75,000
Johns Hopkins University [Member] \| Exclusive License Agreement [Member] \| Therapeutic Field [Member]
Milestone fees	1,600,000
Johns Hopkins University [Member] \| Exclusive License Agreement [Member] \| Regulatory and Commercial Milestones [Member]
Milestone fees	400,000
Johns Hopkins University [Member] \| Exclusive License Agreement [Member] \| Non-clinical field [Member]
Milestone fees	$ 100,000

XML 53 R41.htm IDEA: XBRL DOCUMENT

Convertible Notes - Additional Information (Detail) - USD ($)		1 Months Ended			3 Months Ended
	Feb. 11, 2021	Sep. 30, 2020	Jul. 31, 2020	Apr. 30, 2020	Mar. 31, 2021	Jan. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Amortization of debt issuance costs					$ 256,212
Derivative liability					0
Amortization of debt issuance costs and discounts					$ 613,770
Convertible Debt
Debt Instrument [Line Items]
Debt instrument, face amount				$ 15,000,000		$ 9,031,480
Debt instrument, interest rate				6.00%	6.00%
Debt instrument, additional closing lock in period		190 days	150 days	90 days
Debt instrument, maturity date					Apr. 23, 2021
Debt instrument, convertible, price percentage					80.00%
Debt instrument fully diluted capitalization					$ 85,000,000
Debt instrument, redemption price, percentage of principal amount redeemed					90.00%
Debt instrument, redemption amount			$ 50,000,000		$ 125,000,000
Derivative liability					1,982,594
Interest expense					$ 217,593
Fair value of derivative liability of convertible notes							$ 722,518
Debt conversion converted instrument net of amortization of debt discounts derecognized Into equity	$ 30,252,056
Debt instrument effective interest rate during the period					25.00%
Debt instrument unamortized debt issuance costs								$ 116,636
Debt instrument unamortized debt discount								$ 2,383,986

XML 54 R42.htm IDEA: XBRL DOCUMENT

Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended
	Feb. 11, 2021	Jan. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Proceeds From Issuance Of IPO			$ 115,503,948
Common stock, shares authorized	250,000,000		250,000,000	250,000,000
Common stock, par value	$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,896
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Convertible Debt
Class of Stock [Line Items]
Debt conversion, converted instrument, amount	$ 31,272,224
Debt conversion, converted instrument, shares issued	3,669,010
Common Class A \| IPO
Class of Stock [Line Items]
Stock issued during period shares	7,441,650
Shares issued price per share	$ 17.00
Proceeds From Issuance Of IPO	$ 115,191,259
Redeemable convertible preferred stock
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding	175,137,398
Convertible Preferred Stock, Shares Issued upon Conversion	10,144,052
Series A Redeemable Convertible Preferred Stock
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			145,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		145,000
Temporary Equity Stock Issued During Period Shares New Issues		145,000	145,000

XML 55 R43.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2018	Jun. 01, 2018	Mar. 01, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation shares reserved	2,757,556		1,741,770
Share based compensation shares available for issuance	1,586,365
Share based compensation weighted average fair value of the options granted	$ 11.64	$ 4.04
Share based compensation fair value of stock options vested	$ 800,000	$ 400,000
Share based compensation intrinsic value of stock options exercised	232,268	$ 0
Stock options unrecognized compensation expense	$ 15.3
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock options unrecognized compensation expense period for recognition	3 years 4 months 17 days
The 2017 Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation shares reserved					660,838
The 2018 Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation shares reserved				1,809,143
The 2021 Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment award expiration period	10 years
The 2021 Plan \| Minimum [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment award vesting period	1 year
The 2021 Plan \| Maximum [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment award vesting period	4 years

XML 56 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 1,197,444	$ 318,962
Research and development expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	204,330	82,743
General and administrative expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 993,114	$ 236,219

XML 57 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Option Activity (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Stock options beginning balance \| shares	2,233,185
Stock options granted \| shares	1,170,891
Stock options exercised \| shares	(65,013)
Stock options cancelled \| shares	(772)
Stock options forfeited \| shares	(192,243)
Stock options ending balance \| shares	3,146,048
Stock options vested or expected to vest \| shares	3,146,048
Stock options exercisable \| shares	1,730,292
Stock options shares unvested \| shares	1,415,786
Weighted average exercise price beginning balance \| $ / shares	$ 3.52
Weighted average exercise price granted \| $ / shares	17.00
Weighted average exercise price exercised \| $ / shares	4.56
Weighted average exercise price cancelled \| $ / shares	4.31
Weighted average exercise price forfeited \| $ / shares	4.83
Weighted average exercise price ending balance \| $ / shares	8.44
Weighted average exercise price vested or expected to vest \| $ / shares	8.44
Weighted average exercise price exercisable \| $ / shares	3.18
Weighted average exercise price unvested \| $ / shares	$ 14.86
Weighted average remaining contractual term	7 years 11 months 23 days
Weighted average remaining contractual term vested or expected to vest	7 years 11 months 23 days
Weighted average remaining contractual term exercisable	6 years 7 months 20 days
Weighted average remaining contractual term unvested	9 years 7 months 17 days
Aggregate intrinsic value \| $	$ 33.5
Aggregate intrinsic value vested or expected to vest \| $	33.5
Aggregate intrinsic value exercisable \| $	27.5
Aggregate intrinsic value unvested \| $	$ 6.0

XML 58 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Expected volatility	79.80%
Expected volatility	81.00%
Expected volatility		100.00%
Risk-free interest rate	0.60%	0.70%
Risk-free interest rate	0.70%	0.74%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Expected term	5 years 6 months	5 years 3 months 18 days
Maximum [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Expected term	6 years	6 years

XML 59 R47.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders - Summary of Basic and Diluted Earnings Per Share (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Net loss	$ (8,546,551)	$ (6,315,508)
Accumulated dividends on Redeemable Convertible Preferred Stock	(377,562)	(815,516)
Net loss available to common stockholders'	$ (8,924,113)	$ (7,131,024)
Basic and diluted net loss per common share	$ (0.71)	$ (5.68)
Basic and diluted weighted average common shares outstanding	12,633,123	1,254,681

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

XML 60 R48.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average common shares outstanding	9,939,688	14,374,460
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average common shares outstanding	3,146,048	2,242,145
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average common shares outstanding	4,733,929	10,135,735
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average common shares outstanding	2,059,100	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average common shares outstanding	611	14,480

XML 61 R49.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%	0.00%
Uncertain tax positions	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 62 R50.htm IDEA: XBRL DOCUMENT

Employee Benefit Plan - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Retirement Benefits [Abstract]
Employer discretionary contribution amount	$ 40,233	$ 32,749

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 128 321 1 false 48 0 false 5 false false R1.htm 1001 - Document - Cover Page Sheet http://nex.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Balance Sheets Sheet http://nex.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Balance Sheets (Parenthetical) Sheet http://nex.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Statements Of Operations Sheet http://nex.com/role/StatementsOfOperations Statements Of Operations Statements 4 false false R5.htm 1005 - Statement - Statements Of Comprehensive Loss Sheet http://nex.com/role/StatementsOfComprehensiveLoss Statements Of Comprehensive Loss Statements 5 false false R6.htm 1006 - Statement - Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Deficit Sheet http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersDeficit Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Deficit Statements 6 false false R7.htm 1007 - Statement - Statements Of Cash Flows Sheet http://nex.com/role/StatementsOfCashFlows Statements Of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://nex.com/role/NatureOfTheBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 8 false false R9.htm 1009 - Disclosure - Basis of Presentation Sheet http://nex.com/role/BasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 1010 - Disclosure - Cash and Cash Equivalents and Restricted Cash Sheet http://nex.com/role/CashAndCashEquivalentsAndRestrictedCash Cash and Cash Equivalents and Restricted Cash Notes 10 false false R11.htm 1011 - Disclosure - Fair Value Measurements Sheet http://nex.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 1012 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://nex.com/role/PrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 12 false false R13.htm 1013 - Disclosure - Property and Equipment Sheet http://nex.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 1014 - Disclosure - Accrued Expenses Sheet http://nex.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 1015 - Disclosure - Commitments and Contingencies Sheet http://nex.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Convertible Notes Notes http://nex.com/role/ConvertibleNotes Convertible Notes Notes 16 false false R17.htm 1017 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit Sheet http://nex.com/role/SeriesARedeemableConvertiblePreferredStockAndStockholdersDeficit Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit Notes 17 false false R18.htm 1018 - Disclosure - Stock-Based Compensation Sheet http://nex.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 1019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://nex.com/role/NetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 19 false false R20.htm 1020 - Disclosure - Income Taxes Sheet http://nex.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 1021 - Disclosure - Employee Benefit Plan Sheet http://nex.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 21 false false R22.htm 1022 - Disclosure - Basis of Presentation (Policies) Sheet http://nex.com/role/BasisOfPresentationPolicies Basis of Presentation (Policies) Policies 22 false false R23.htm 1023 - Disclosure - Cash and Cash Equivalents and Restricted Cash (Tables) Sheet http://nex.com/role/CashAndCashEquivalentsAndRestrictedCashTables Cash and Cash Equivalents and Restricted Cash (Tables) Tables http://nex.com/role/CashAndCashEquivalentsAndRestrictedCash 23 false false R24.htm 1024 - Disclosure - Fair Value Measurements (Tables) Sheet http://nex.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://nex.com/role/FairValueMeasurements 24 false false R25.htm 1025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://nex.com/role/PrepaidExpensesAndOtherCurrentAssets 25 false false R26.htm 1026 - Disclosure - Property and Equipment (Tables) Sheet http://nex.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://nex.com/role/PropertyAndEquipment 26 false false R27.htm 1027 - Disclosure - Accrued Expenses (Tables) Sheet http://nex.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://nex.com/role/AccruedExpenses 27 false false R28.htm 1028 - Disclosure - Stock-Based Compensation (Tables) Sheet http://nex.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://nex.com/role/StockBasedCompensation 28 false false R29.htm 1029 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://nex.com/role/NetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://nex.com/role/NetLossPerShareAttributableToCommonStockholders 29 false false R30.htm 1030 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) Sheet http://nex.com/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of the Business and Basis of Presentation - Additional Information (Detail) Details 30 false false R31.htm 1031 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://nex.com/role/BasisOfPresentationAdditionalInformationDetail Basis of Presentation - Additional Information (Detail) Details 31 false false R32.htm 1032 - Disclosure - Cash and Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents And Restricted Cash (Detail) Sheet http://nex.com/role/CashAndCashEquivalentsAndRestrictedCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Cash and Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents And Restricted Cash (Detail) Details 32 false false R33.htm 1033 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements Categorized As Level 3 (Detail) Sheet http://nex.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsCategorizedAsLevel3Detail Fair Value Measurements - Summary of Fair Value Measurements Categorized As Level 3 (Detail) Details 33 false false R34.htm 1034 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurements of the Convertible Notes (Detail) Notes http://nex.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOfTheConvertibleNotesDetail Fair Value Measurements - Summary of Fair Value Measurements of the Convertible Notes (Detail) Details 34 false false R35.htm 1035 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://nex.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 35 false false R36.htm 1036 - Disclosure - Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail) Sheet http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail) Details 36 false false R37.htm 1037 - Disclosure - Property and Equipment - Summary of Property And Equipment (Detail) Sheet http://nex.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail Property and Equipment - Summary of Property And Equipment (Detail) Details 37 false false R38.htm 1038 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://nex.com/role/PropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 38 false false R39.htm 1039 - Disclosure - Accrued Expenses - Summary of Components of Accrued Expenses (Detail) Sheet http://nex.com/role/AccruedExpensesSummaryOfComponentsOfAccruedExpensesDetail Accrued Expenses - Summary of Components of Accrued Expenses (Detail) Details 39 false false R40.htm 1040 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://nex.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 40 false false R41.htm 1041 - Disclosure - Convertible Notes - Additional Information (Detail) Notes http://nex.com/role/ConvertibleNotesAdditionalInformationDetail Convertible Notes - Additional Information (Detail) Details 41 false false R42.htm 1042 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) Sheet http://nex.com/role/SeriesARedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetail Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) Details 42 false false R43.htm 1043 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://nex.com/role/StockBasedCompensationAdditionalInformationDetail Stock-based Compensation - Additional Information (Detail) Details 43 false false R44.htm 1044 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail) Sheet http://nex.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail) Details 44 false false R45.htm 1045 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail) Sheet http://nex.com/role/StockBasedCompensationSummaryOfOptionActivityDetail Stock-Based Compensation - Summary of Option Activity (Detail) Details 45 false false R46.htm 1046 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail) Sheet http://nex.com/role/StockBasedCompensationSummaryOfBlackScholesOptionPricingModelDetail Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail) Details 46 false false R47.htm 1047 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Basic and Diluted Earnings Per Share (Detail) Sheet http://nex.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfBasicAndDilutedEarningsPerShareDetail Net Loss Per Share Attributable to Common Stockholders - Summary of Basic and Diluted Earnings Per Share (Detail) Details 47 false false R48.htm 1048 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Outstanding (Detail) Sheet http://nex.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesOutstandingDetail Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Outstanding (Detail) Details 48 false false R49.htm 1049 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://nex.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 49 false false R50.htm 1050 - Disclosure - Employee Benefit Plan - Additional Information (Detail) Sheet http://nex.com/role/EmployeeBenefitPlanAdditionalInformationDetail Employee Benefit Plan - Additional Information (Detail) Details 50 false false All Reports Book All Reports nexi-20210331.xml nexi-20210331.xsd nexi-20210331_cal.xml nexi-20210331_def.xml nexi-20210331_lab.xml nexi-20210331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 68 0001193125-21-163695-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-163695-xbrl.zip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end